Original Article
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
N Engl J Med 2005; 352:1977-1984May 12, 2005
- Abstract
Background
In 2002, we reported the initial results of a trial comparing radical prostatectomy with watchful waiting in the management of early prostate cancer. After three more years of follow-up, we report estimated 10-year results.
Methods
From October 1989 through February 1999, 695 men with early prostate cancer (mean age, 64.7 years) were randomly assigned to radical prostatectomy (347 men) or watchful waiting (348 men). The follow-up was complete through 2003, with blinded evaluation of the causes of death. The primary end point was death due to prostate cancer; the secondary end points were death from any cause, metastasis, and local progression.
Results
During a median of 8.2 years of follow-up, 83 men in the surgery group and 106 men in the watchful-waiting group died (P=0.04). In 30 of the 347 men assigned to surgery (8.6 percent) and 50 of the 348 men assigned to watchful waiting (14.4 percent), death was due to prostate cancer. The difference in the cumulative incidence of death due to prostate cancer increased from 2.0 percentage points after 5 years to 5.3 percentage points after 10 years, for a relative risk of 0.56 (95 percent confidence interval, 0.36 to 0.88; P=0.01 by Gray's test). For distant metastasis, the corresponding increase was from 1.7 to 10.2 percentage points, for a relative risk in the surgery group of 0.60 (95 percent confidence interval, 0.42 to 0.86; P=0.004 by Gray's test), and for local progression, the increase was from 19.1 to 25.1 percentage points, for a relative risk of 0.33 (95 percent confidence interval, 0.25 to 0.44; P<0.001 by Gray's test).
Conclusions
Radical prostatectomy reduces disease-specific mortality, overall mortality, and the risks of metastasis and local progression. The absolute reduction in the risk of death after 10 years is small, but the reductions in the risks of metastasis and local tumor progression are substantial.
Media in This Article
Figure 1
Cumulative Incidence of Death from Prostate Cancer in the Two Study Groups Overall (Panel A) and According to Age (Panel B).Figure 2
Cumulative Incidence of Distant Metastasis (Panel A) and of Death from Any Cause (Panel B).Article Activity
- Article
Radical prostatectomy is becoming one of the most common major surgical procedures in many Western countries. In the United States alone, an estimated 60,000 men undergo this operation each year. However, to our knowledge, only one randomized trial quantified the benefit of radical prostatectomy.1
In 2002, we presented the results of a clinical trial in which radical prostatectomy was compared with watchful waiting in the management of early prostate cancer.1 Our analysis was based on a mean follow-up time of 6.2 years, a relatively short period in relation to the often long natural history of early prostate cancer.2 We found that, as compared with watchful waiting, radical prostatectomy reduced the risk of death due to prostate cancer by 50 percent and the risk of distant metastasis by 37 percent, but there was no statistically significant reduction in overall mortality.
We now present a second analysis after an additional three years of follow-up, in accordance with the study protocol. Our main purpose was to analyze two hypotheses: first, that the relative reduction in the risk of death due to prostate cancer after surgery increases over time because removal of the primary tumor prevents metastasis and, second, that radical prostatectomy significantly improves overall survival.
Methods
Study Design
Details concerning study design and methods have been published previously.1 The protocol, defined in 1988, is available with the full text of this article at www.nejm.org.
From 1989 to 1999, 695 men from 14 centers in Sweden, Finland, and Iceland were enrolled. The eligibility criteria included an age under 75 years; the presence of newly diagnosed, untreated, localized prostate cancer, as verified by cytologic or histologic examination, with a tumor stage of T0d (later changed to T1b), T1, or T2 (T1c was included in 1994)3,4 (Table 1Table 1
Baseline Characteristics of the 695 Men Enrolled in the Study.); a health status that would permit radical prostatectomy; and a life expectancy of more than 10 years. The tumor had to be well differentiated to moderately well differentiated, according to the definition established by the World Health Organization.5 Patients had to have a bone scan that showed no abnormalities and a prostate-specific antigen (PSA) level of less than 50 ng per milliliter. If the diagnosis had been established after transurethral resection, at least six blocks of prostate tissue should have been examined. After oral informed consent was received from eligible patients, they were randomly assigned to undergo either radical prostatectomy or watchful waiting through a telephone service outside the clinics. Stratification was made according to tumor grade and randomization center.For men assigned to the radical-prostatectomy group, surgery started with dissection of the pelvic lymph nodes.6 If there were no signs of metastasis in frozen sections, the operation was continued with retropubic radical prostatectomy.7 The men in the watchful-waiting group received no initial treatment other than the transurethral resection some of them had already undergone.
Hormonal treatment was recommended for men with symptomatic local progression in the radical-prostatectomy group and for those with disseminated disease in both groups. Transurethral resection was recommended as the initial treatment for men with urinary obstruction in the watchful-waiting group. In January 2003, an amendment to the protocol allowed men in both groups to begin hormonal therapy if their physicians advised it.
Follow-up and Definition of Clinical Events
The participants were seen every six months during the first two years and then annually for a clinical examination and blood tests (to evaluate hemoglobin, PSA, alkaline phosphatase, and creatinine levels). A bone scan and a chest radiograph were obtained annually until 1997; thereafter, chest radiographs were obtained only once a year for the first two years after randomization. The clinical follow-up continued for all patients except nine, who underwent blood tests (including tests for PSA levels) and bone scanning when possible but who did not have clinical visits owing to old age and coexisting illnesses. Beginning in 2003, bone scans were allowed every second year if the patient had no biochemical or clinical signs of progression. In 2001, a pathological review of cytologic and histologic data that were available at inclusion was carried out. For the purpose of this analysis, all patient records were retrieved and individually reviewed for new events.
An independent end-point committee determined the cause of death on the basis of standardized extractions from the patient files; for this determination, the treatment group was not revealed. The committee used six categories of cause of death: prostate cancer; another main cause but with distant metastases, regardless of local status; another main cause but with local progression, without distant metastases; another main cause, but with local progression and unknown status concerning distant metastases; another main cause, with no evidence of tumor recurrence, tumor progression, or metastases; and another main cause within the first month after randomization.
In the radical-prostatectomy group, local progression was defined as the presence of a histologically confirmed local tumor. In the watchful-waiting group, men with palpable transcapsular tumor growth or with symptoms of urinary obstruction that necessitated intervention were classified as having local progression. Distant metastases were considered present when bone scans, skeletal radiographs, computed tomographic scans, or chest radiographs revealed metastases or if lymph nodes at sites other than the regional sites showed cytologic or histologic evidence of prostate cancer.
Statistical Analysis
There were four main end points: disease-specific death, with death due to prostate cancer (the first cause-of-death category) considered the event and death from other causes treated as a competing risk; distant metastasis, with its diagnosis considered the event and death from other causes treated as a competing risk; local progression, with death treated as a competing risk; and death from any cause.
All analyses were carried out in accordance with the intention-to-treat principle. Relative risks (with 95 percent confidence intervals) and differences in cumulative incidence (with 95 percent confidence intervals) were used as measures of effect for each end point. Gray's test8 was used to test the hypothesis that there was no difference between the treatment groups; a P value of less than 0.05 (two-sided) was considered to indicate statistical significance. The relative risks were estimated from the Cox proportional-hazards model. Cumulative incidence (calculated in terms of integrated subdensity) rather than cumulative hazard (integrated subhazard) was used in the acknowledgment that the end points constitute competing events.9 The results presented here and in the previous report1 involved low absolute risks for disease-specific death and death from any cause, with no sensitivity to whether cumulative incidence rates or cumulative hazard rates were used.
Effect modification was first investigated through simple stratified analyses. For all end points, three prespecified subgroup analyses were carried out: analysis according to age at diagnosis — less than 65 years of age as compared with 65 years of age or older; analysis according to PSA level at diagnosis — 10 ng per milliliter or lower as compared with more than 10 ng per milliliter; and analysis according to the Gleason score of the prerandomization biopsy specimen — lower than 7 as compared with 7 or more (on a scale of 2 to 10, with 10 indicating the most poorly differentiated tumors). Any modification of the effect of radical prostatectomy according to subgroup was tested by a Cox proportional-hazards model, which included an interaction term between subgroup category and randomization group. In a second step, we further explored the interaction by including the possible effect modifier (age, PSA level at diagnosis, or Gleason score) as a continuous variable. When there was an indication of effect modification, we further controlled for the PSA level at diagnosis, the tumor stage, the Gleason score, and the year at inclusion by adding these as additional covariates in the Cox proportional-hazards model.
Results
We randomly assigned 347 men to radical prostatectomy and 348 to watchful waiting. Relevant characteristics at the time of inclusion were similar in the two groups. Most patients (76 percent) had stage T2 tumors (i.e., the tumor was confined within the prostate), and in only 12 percent were T1c (nonpalpable) tumors detected by means of PSA testing (Table 1). At the end of 2003, 21 men assigned to radical prostatectomy had not undergone surgery, and 43 assigned to watchful waiting had undergone curative treatment. Lymph-node metastases, which precluded surgery, were found in frozen sections from 23 men in the radical-prostatectomy group.
During follow-up, fewer men in the radical-prostatectomy group than in the watchful-waiting group died of prostate cancer (30 vs. 50, P=0.01). As for causes of death other than prostate cancer, the numbers were similar in the two groups (53 and 56, respectively). However, among men who died from causes other than prostate cancer, a larger number in the watchful-waiting group had metastases or local progression. In terms of death from any cause, 23 more men in the watchful-waiting group than in the radical-prostatectomy group died (106 vs. 83, P=0.04) (Table 2Table 2
Causes of Death, According to the Final Consensus of the End-Point Committee.).Disease-Specific Mortality
The difference between the two groups in the cumulative incidence of death from prostate cancer increased over time, from 2 percentage points (95 percent confidence interval, –0.6 to 4.7) after five years of follow-up to 5.3 percentage points (95 percent confidence interval, –0.3 to 11.0) after 10 years, in favor of radical prostatectomy. The relative risk among men assigned to radical prostatectomy, as compared with those assigned to watchful waiting, was 0.56 (95 percent confidence interval, 0.36 to 0.88) (Figure 1AFigure 1
Cumulative Incidence of Death from Prostate Cancer in the Two Study Groups Overall (Panel A) and According to Age (Panel B). and Table 3Table 3
Cumulative Incidence of the Main End Points and Corresponding Relative Risks.).Distant Metastases
The cumulative incidence of distant metastases was similar in the two groups during the first five years (8.1 percent in the radical-prostatectomy group and 9.8 percent in the watchful-waiting group, P=0.42). However, a difference emerged after that time: at the second follow-up, 50 of the 347 men in the radical-prostatectomy group had distant metastases, as compared with 79 of the 348 men in the watchful-waiting group. In the radical-prostatectomy group, the absolute risk reduction at 10 years was 10.2 percentage points (95 percent confidence interval, 3.1 to 17.2), corresponding to a relative risk of 0.60 (95 percent confidence interval, 0.42 to 0.86) (Figure 2AFigure 2
Cumulative Incidence of Distant Metastasis (Panel A) and of Death from Any Cause (Panel B). and Table 3).Local Progression
The difference between the two groups in the cumulative incidence of local progression was statistically significant after five years of follow-up (8.1 percent in the radical-prostatectomy group vs. 27.2 percent in the watchful-waiting group, P<0.01); the difference increased over time, to 64 men with local progression among the 347 in the prostatectomy group, as compared with 149 men among the 348 in the watchful-waiting group, at the second follow-up. The difference in the absolute risk reduction after 10 years was 25.1 percentage points (19.2 percent vs. 44.3 percent), corresponding to a relative risk in the radical-prostatectomy group of 0.33 (95 percent confidence interval, 0.25 to 0.44) (Table 3).
Overall Mortality
The cumulative incidence of death from any cause was similar in the two groups during the first five years (7.8 percent for radical prostatectomy vs. 9.8 percent for watchful waiting). At the last follow-up, 83 of 347 men in the radical-prostatectomy group and 106 of 348 in the watchful-waiting group had died. After randomization to radical prostatectomy, the absolute reduction in the risk of death from any cause after 10 years was 5.0 percentage points, corresponding to a relative risk of 0.74 (95 percent confidence interval, 0.56 to 0.99; P=0.04 by Gray's test) (Figure 2B and Table 3).
Other Treatments
Hormonal treatment was administered less often in the radical-prostatectomy group than in the watchful-waiting group (110 of 347 patients vs. 177 of 348, P<0.01). The mean time to hormonal treatment was 4.5 years in the radical-prostatectomy group and 4.8 years in the watchful-waiting group. Palliative radiation was also administered less often in the radical-prostatectomy group than in the watchful-waiting group (29 patients vs. 38 patients, P=0.30), as was laminectomy (4 patients vs.11 patients, P=0.04).
Subgroup Analyses
In planned, simple stratified analyses, we found that the benefit of radical prostatectomy in terms of disease-specific mortality differed according to age group but not according to the PSA level at diagnosis or the Gleason score. A further investigation of disease-specific mortality with the use of a Cox proportional-hazards model that included the randomization group, the patient's age as a continuous variable, and an interaction term showed that the interaction term was statistically significant (P=0.03). When the same model was augmented with the PSA level at diagnosis, the tumor stage, the Gleason score, and the year at inclusion, the P value for the interaction term shifted to 0.08. For overall mortality, the P value for the interaction term in the corresponding two analyses shifted only marginally and remained less than 0.01. The cumulative incidence of death from prostate cancer in men under 65 years of age in the watchful-waiting group was 19.2 percent at 10 years. This was markedly higher than the cumulative incidence of death in the other subgroups defined according to randomization group and age, for which the incidence varied from 8.5 percent to 11.5 percent (Figure 1B).
Discussion
In this comparison of radical prostatectomy with watchful waiting for patients with prostate cancer, the 10-year absolute differences in disease-specific and overall mortality were statistically significant, by 5.3 (P=0.01) and 5.0 (P=0.04) percentage points, respectively, in favor of radical prostatectomy. In addition, the cumulative incidence of distant metastasis was 10.2 percentage points lower in the surgery group than in the watchful-waiting group. Because clinical manifestations of disseminated disease virtually always precede death,2 this finding might herald a further lowering of the risk of death due to prostate cancer in the radical-prostatectomy group after a longer period of follow-up. We found no evidence that the benefit of radical prostatectomy was exaggerated by more frequent administration of hormonal treatment, since hormonal therapy was given less often in the radical-prostatectomy group than in the watchful-waiting group (110 patients vs. 177 patients).
We found that the reduction in disease-specific mortality as a result of radical prostatectomy was greatest among, or even limited to, patients younger than 65 years. The multivariate analyses indicated that this finding was attributable, only to a limited extent, to differences between younger and older men in the distribution of PSA levels or Gleason scores; however, there may have been other differences in characteristics between younger and older men at the time of inclusion. These results have limited interpretability for two additional reasons: they were based on small numbers, since the study was not powered to analyze subgroups, and the analysis was exploratory rather than based on any a priori biologic hypothesis. Therefore, the results of the subgroup analyses should be an incentive to conduct further research rather than to introduce an immediate change in clinical practice.
Observational cohort studies have analyzed survival rates among patients whose cancer was managed by watchful waiting. After 10 years of follow-up, such studies yielded disease-specific survival rates of 87 percent,10 86 percent,11 and 83 percent.12 In our trial, the corresponding 10-year figure was 85 percent. The similar prognosis among patients randomly assigned to watchful waiting in our trial and those analyzed in observational studies indicates that our findings are generalizable to patients in similar settings. If watchful waiting with curative intervention in patients with rising PSA levels (as detected with active monitoring) yields better survival than does traditional watchful waiting, the difference between watchful waiting and primary surgery should diminish. As yet, however, there is no evidence from a randomized trial that the monitoring of PSA levels with accompanying curative intervention will yield better results than will watchful waiting as used in this trial and in the observational studies.
In this follow-up period, we found a substantial absolute difference between the two groups in terms of local progression (which can cause problems with the micturition, pain, and anxiety). Moreover, the need for hormonal treatment increased in frequency in the watchful-waiting group, as did the need for palliative radiation; both types of treatment were associated with side effects that influenced patients' quality of life and well-being. Thus, the more immediate, though stable, side effects associated with surgery13 (predominantly, impotence and incontinence) and reported previously for this study,14 should be weighed against the increasing incidence of symptoms and use of treatments after the progression of disease in the watchful-waiting group. However, for several reasons, a reevaluation of the costs and benefits of radical prostatectomy in the era of widespread screening is necessary: the number of patients needed to treat may be high, and the lead time to the onset of symptoms and treatment may be long in those undergoing monitoring, but the removal of small tumors may facilitate surgery and result in fewer side effects.
Our 10-year estimates show that radical prostatectomy is associated with a statistically significant reduction in all the end points that we investigated, with a relative reduction of 44 percent in mortality due to prostate cancer, of 26 percent in overall mortality, of 40 percent in the risk of distant metastasis, and of 67 percent in local progression. Since, in absolute terms, the reduction in mortality is moderate, clinical decision making and patient counseling will remain difficult. The additional finding that radical prostatectomy substantially reduces the risk of metastasis and symptomatic local tumor growth may, however, be of some help in guiding therapy, and we expect that the benefits of this surgery will increase during longer periods of follow-up.
Supported by the Swedish Cancer Society.
Drs. Bill-Axelson and Holmberg contributed equally to the article.
Source Information
From the Department of Urology (A.B.-A., M.H., B.J.N.), the Regional Oncologic Center (L.H., H.G.), and the Department of Pathology (C.B.), University Hospital, Uppsala, Sweden; the Departments of Urology (M.R.) and Pathology (S.N.), University of Helsinki and University Hospital of Helsinki, Helsinki; the Department of Urology (S.-O.A., J.-E.J.) and the Center for Assessment of Medical Technology (J.-E.J.), Örebro University Hospital, Örebro, Sweden; the Department of Urology, Borås Hospital, Borås, Sweden (S.B.); the Department of Urology, Linköping University Hospital, Linköping, Sweden (A.S.); the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (J.P., H.-O.A.); and the Department of Epidemiology, Harvard School of Public Health, Boston (H.-O.A.).
Address reprint requests to Dr. Bill-Axelson at the Department of Urology, University Hospital, SE-751 85 Uppsala, Sweden, or at anna.bill.axelson@akademiska.se.
The participants in the Scandinavian Prostate Cancer Group Study No. 4 are listed in the Appendix.
Appendix
The participants in the Scandinavian Prostate Cancer Group Study No. 4 were as follows: Protocol Committee — H.-O. Adami and J.-E. Johansson; Steering Committee — H.-O. Adami, A. Bill-Axelson, L. Holmberg, J.-E. Johansson (principal investigator), and B.-J. Norlén; Statistical Analysis — L. Holmberg, H. Garmo, and J. Palmgren; Manuscript Preparation — H.-O. Adami, A. Bill-Axelson, and L. Holmberg; Monitoring — A. Bill-Axelson and B. Gobén; Study Group, Recruitment, and Data Collection: Borås, Sweden — S. Bratell; Eskilstuna, Sweden — T. Lindeborg; Helsinki — M. Ruutu and J. Salo; Linköping, Sweden — A. Spångberg; Lund, Sweden — P. Elfving; Reykjavik, Iceland — G. Einarsson; Stockholm — J. Adolfsson, P. Ekman, P. -O. Hedlund, and H. Wikström; Uleåborg, Finland — O. Lukkarinen; Uppsala, Sweden — A. Bill-Axelson, M. Häggman, and B.-J. Norlén; Västerås, Sweden — L. Karlberg; Växjö, Sweden — G. Hagberg; Örebro, Sweden — S.-O. Andersson and J. -E. Johansson; Reference Pathologists — C. Busch (chair), M. de la Torre, A. Lindgren, and S. Nordling; End Point Committee — J.-E. Damber, Department of Urology, University Hospital, Göteborg, Sweden; A. Lindgren, Department of Pathology, University Hospital, Uppsala, Sweden; E. Varenhorst (chair), Department of Urology, University Hospital, Linköping, Sweden; External Review Committee — P.F. Schellhammer, Department of Urology, Eastern Virginia Medical School, Norfolk, Va.; U.E. Studer, Department of Urology, University of Bern, Bern, Switzerland; and R. Sylvester, European Organization for Research and Treatment of Cancer, Brussels.
- References
References
1
Holmberg L ,Bill-Axelson A ,Helgesen F , et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789
Full Text | Web of Science | Medline2
Johansson JE ,Andren O ,Andersson SO , et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-2719
CrossRef | Web of Science | Medline3
Harmer MH, ed. TNM classification of malignant tumours. 3rd ed. rev. Geneva: International Union Against Cancer, 1982.
4
Hermanek P, Sobin LH, eds. TNM classification of malignant tumours. 4th ed. rev. Berlin: Springer-Verlag, 1992.
5
Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours. Geneva: World Health Organization, 1980.
6
Brendler CB ,Cleeve LK ,Anderson EE ,Paulson DF . Staging pelvic lymphadenectomy for carcinoma of the prostate: risk versus benefit. J Urol 1980;124:849-850
Web of Science | Medline7
Walsh PC ,Lepor H . The role of radical prostatectomy in the management of prostatic cancer. Cancer 1987;60:Suppl 3:526-537
CrossRef | Web of Science | Medline8
Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154
CrossRef | Web of Science9
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. Hoboken, N.J.: Wiley, 2002.
10
Chodak GW ,Thisted RA ,Gerber GS , et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248
Full Text | Web of Science | Medline11
Johansson JE ,Holmberg L ,Johansson S ,Bergstrom R ,Adami HO . Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 1997;277:467-471[Erratum, JAMA 1997;278:206.]
CrossRef | Web of Science | Medline12
Adolfsson J ,Steineck G ,Whitmore WF Jr . Recent results of management of palpable clinically localized prostate cancer. Cancer 1993;72:310-322
CrossRef | Web of Science | Medline13
Potosky AL ,Davis WW ,Hoffman RM , et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004;96:1358-1367
CrossRef | Web of Science | Medline14
Steineck G ,Helgesen F ,Adolfsson J , et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-796
Full Text | Web of Science | Medline
- Citing Articles (543)
Citing Articles
1
Xavier Hurtes, Morgan Rouprêt, Christophe Vaessen, Helder Pereira, Benjamin Faivre d'Arcier, Luc Cormier, Franck Bruyère. (2012) Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU Internationalno-no
CrossRef2
Elisabeth Meyer, Ray Rees. (2012) Watchfully waiting: Medical intervention as an optimal investment decision. Journal of Health Economics
CrossRef3
A. Heidenreich, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, N. Mottet, H.P. Schmid, T. van der Kwast, T. Wiegel, F. Zattoni. (2012) EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Actas Urológicas Españolas (English Edition)
CrossRef4
Samarpit Rai, Abhishek Srivastava, Prasanna Sooriakumaran, Ashutosh Tewari. (2012) Advances in imaging the neurovascular bundle. Current Opinion in Urology1
CrossRef5
Osamu Ukimura, Kenneth Faber, Inderbir S. Gill. (2012) Intraprostatic targeting. Current Opinion in Urology1
CrossRef6
Maria Michela Gianino, Mario Galzerano, Barbara Martin, Simone Chiadò Piat, Paolo Gontero. (2012) Costs in Surgical Techniques for Radical Prostatectomy: A Review of the Current State. Urologia Internationalis 88:1, 1-5
CrossRef7
Kam Hung Sidney Yip, Chi-hang Yee, Chi-fai Ng, Nga-yee Lam, Kwan-lun Ho, Wai-kit Ma, Cheuk-man Li, See-ming Hou, Po-chor Tam, Ming-kwong Yiu, Chi-wai Fan. (2011) Robotic Radical Prostatectomy in Hong Kong: A Review of 235 Cases. Journal of Endourology111222131842005
CrossRef8
Mark C. Scholz, Richard Y. Lam, Stephen B. Strum, Dean J. LaBarba, Lauren K. Becker, Patricia Chang, Nojan Farhoumand, Robert I. Jennrich. (2011) Primary Intermittent Androgen Deprivation As Initial Therapy for Men with Newly Diagnosed Prostate Cancer. Clinical Genitourinary Cancer 9:2, 89-94
CrossRef9
B. Joyce Davison, S. Larry Goldenberg. (2011) Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU International 108:11, 1787-1793
CrossRef10
Patrice Forget, Bertrand Tombal, Jean-Louis Scholtès, Jolio Nzimbala, Catherine Meulders, Catherine Legrand, Paul Van Cangh, Jean-Pierre Cosyns, Marc De Kock. (2011) Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer?. European Journal of Anaesthesiology 28:12, 830-835
CrossRef11
Y-H Shao, P C Albertsen, W Shih, C B Roberts, G L Lu-Yao. (2011) The impact of PSA testing frequency on prostate cancer incidence and treatment in older men. Prostate Cancer and Prostatic Diseases 14:4, 332-339
CrossRef12
Brian J. Moran, Paul DeRose, I-Chow Joe Hsu, May Abdel-Wahab, V. Elayne Arterbery, Jay P. Ciezki, Steven J. Frank, James Lloyd Mohler, Seth A. Rosenthal, Carl J. Rossi, Yoshiya Yamada, Gregory S. Merrick. (2011) ACR Appropriateness Criteria® Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology 34:6, 636-647
CrossRef13
Barbara Joyce Davison, Erin Breckon. (2011) Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. Patient Education and Counseling
CrossRef14
G E Tasian, M R Cooperberg, M B Potter, J E Cowan, K L Greene, P R Carroll, J M Chan. (2011) PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer and Prostatic Diseases
CrossRef15
S.S. Rambaran, D. Ouden, M. Kliffen, D.C.D. Lange, O.S. Klaver. (2011) Robotgeassisteerde laparoscopische radicale prostatectomie in een perifeer ziekenhuis: perioperatieve parameters en korte termijn functionele en oncologische resultaten bij de eerste 400 patiënten. Tijdschrift voor Urologie
CrossRef16
David Atkins, Stephanie M. Chang, Gerald Gartlehner, David I. Buckley, Evelyn P. Whitlock, Elise Berliner, David Matchar. (2011) Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of Clinical Epidemiology 64:11, 1198-1207
CrossRef17
Firas Abdollah, Maxine Sun, Jan Schmitges, Zhe Tian, Claudio Jeldres, Alberto Briganti, Shahrohk F. Shariat, Paul Perrotte, Francesco Montorsi, Pierre I. Karakiewicz. (2011) Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis of a Large North American Population-Based Cohort. European Urology 60:5, 920-930
CrossRef18
Julie L. Kasperzyk, William V. Shappley, Stacey A. Kenfield, Lorelei A. Mucci, Tobias Kurth, Jing Ma, Meir J. Stampfer, Martin G. Sanda. (2011) Watchful Waiting and Quality of Life Among Prostate Cancer Survivors in the Physicians' Health Study. The Journal of Urology 186:5, 1862-1867
CrossRef19
Ketul Shah, Ronney Abaza. (2011) Comparison of intraoperative outcomes using the new and old generation da Vinci® robot for robot-assisted laparoscopic prostatectomy. BJU International 108:10, 1642-1645
CrossRef20
C. Leland Rogers, Stephen C. Alder, R. LeGrand Rogers, Scott A. Hopkins, McKay L. Platt, Lane C. Childs, Ronald H. Crouch, Roger S. Hansen, John K. Hayes. (2011) High Dose Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer. The Journal of Urology
CrossRef21
Jennifer Beebe-Dimmer, Vahakn Shahinian. (2011) Tackling overtreatment of prostate cancer. Cancer 117:20, 4576-4578
CrossRef22
Timothy J. Daskivich, Karim Chamie, Lorna Kwan, Jessica Labo, Atreya Dash, Sheldon Greenfield, Mark S. Litwin. (2011) Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 117:20, 4642-4650
CrossRef23
F. R. Schumacher, S. I. Berndt, A. Siddiq, K. B. Jacobs, Z. Wang, S. Lindstrom, V. L. Stevens, C. Chen, A. M. Mondul, R. C. Travis, D. O. Stram, R. A. Eeles, D. F. Easton, G. Giles, J. L. Hopper, D. E. Neal, F. C. Hamdy, J. L. Donovan, K. Muir, A. A. Al Olama, Z. Kote-Jarai, M. Guy, G. Severi, H. Gronberg, W. B. Isaacs, R. Karlsson, F. Wiklund, J. Xu, N. E. Allen, G. L. Andriole, A. Barricarte, H. Boeing, H. Bas Bueno-de-Mesquita, E. D. Crawford, W. R. Diver, C. A. Gonzalez, J. M. Gaziano, E. L. Giovannucci, M. Johansson, L. Le Marchand, J. Ma, S. Sieri, P. Stattin, M. J. Stampfer, A. Tjonneland, P. Vineis, J. Virtamo, U. Vogel, S. J. Weinstein, M. Yeager, M. J. Thun, L. N. Kolonel, B. E. Henderson, D. Albanes, R. B. Hayes, H. Spencer Feigelson, E. Riboli, D. J. Hunter, S. J. Chanock, C. A. Haiman, P. Kraft. (2011) Genome-wide association study identifies new prostate cancer susceptibility loci. Human Molecular Genetics 20:19, 3867-3875
CrossRef24
Andrew J. Stephenson, Michel Bolla, Alberto Briganti, Cesare Cozzarini, Judd W. Moul, Mack Roach III, Hein van Poppel, Anthony Zietman. (2011) Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. European Urology
CrossRef25
Karim Chamie, Timothy J. Daskivich, Lorna Kwan, Jessica Labo, Atreya Dash, Sheldon Greenfield, Mark S. Litwin. (2011) Comorbidities, Treatment and Ensuing Survival in Men with Prostate Cancer. Journal of General Internal Medicine
CrossRef26
Leonardo Kayat Bittencourt, Jelle O. Barentsz, Luiz Carlos Duarte Miranda, Emerson Leandro Gasparetto. (2011) Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. European Radiology
CrossRef27
Johan Lyth, Swen-Olof Andersson, Ove Andrén, Jan-Erik Johansson, Per Carlsson, Nosrat Shahsavar. (2011) A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer. Scandinavian Journal of Urology and Nephrology1-7
CrossRef28
Andreas E. Nilsson, Stefan Carlsson, Eva Johansson, Martin N. Jonsson, Christofer Adding, Tommy Nyberg, Gunnar Steineck, N. Peter Wiklund. (2011) Orgasm-Associated Urinary Incontinence and Sexual Life after Radical Prostatectomy. The Journal of Sexual Medicine 8:9, 2632-2639
CrossRef29
Abhay R. Shelke, Supriya G. Mohile. (2011) Treating Prostate Cancer in Elderly Men: How Does Aging Affect the Outcome?. Current Treatment Options in Oncology 12:3, 263-275
CrossRef30
Kent H. Nouri, Eldor L. Brish. (2011) Spinal Cord Stimulation for Testicular Pain. Pain Medicine 12:9, 1435-1438
CrossRef31
T. Gruschwitz, M.-O. Grimm. (2011) Früherkennung in der Urologie. Der Onkologe
CrossRef32
James G. Kench, David R. Clouston, Warick Delprado, Thomas Eade, David Ellis, Lisa G. Horvath, Hemamali Samaratunga, Jurgen Stahl, Alan M. F. Stapleton, Lars Egevad, John R. Srigley, Brett Delahunt. (2011) Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology 43:5, 410-419
CrossRef33
Anton Ponholzer, Ferdinand Steinbacher, Stephan Madersbacher, Paul Schramek. (2011) Aktuelle Therapie des fortgeschrittenen Prostatakarzinoms. Wiener Medizinische Wochenschrift 161:15-16, 377-381
CrossRef34
Mathieu Rouanne, Christophe Vaessen, Marc-Olivier Bitker, Emmanuel Chartier-Kastler, Morgan Rouprêt. (2011) Outcome of a Modified York Mason Technique in Men With Iatrogenic Urethrorectal Fistula After Radical Prostatectomy. Diseases of the Colon & Rectum 54:8, 1008-1013
CrossRef35
Raphaële Renard-Penna, Morgan Rouprêt, Eva Comperat, Amine Ayed, Mathieu Coudert, Pierre Mozer, Evanguelos Xylinas, Marc-Olivier Bitker, Philippe Grenier. (2011) Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: Results from a prospective study. Urologic Oncology: Seminars and Original Investigations
CrossRef36
Charles D. Scales, Steven E. Canfield. (2011) Advanced topics in evidence-based urological oncology: Using results of a subgroup analysis. Urologic Oncology: Seminars and Original Investigations 29:4, 462-466
CrossRef37
Shabbir M.H. Alibhai, Anne M. Horgan. (2011) Cancer screening in older adults: What to do when we don't know. Journal of Geriatric Oncology 2:3, 149-160
CrossRef38
Sung Kyu Hong, Jong Jin Oh, Sung Jin Jeong, Chang Wook Jeong, In Sung Kim, Jung Min Park, Seok-Soo Byun, Gheeyoung Choe, Hak Jong Lee, Sang Eun Lee. (2011) Prediction of outcomes after radical prostatectomy in patients diagnosed with prostate cancer of biopsy gleason score ≥ 8 via contemporary multi (≥12)-core prostate biopsy. BJU International 108:2, 217-222
CrossRef39
Amit R. Patel, Andrew J. Stephenson. (2011) Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?. Nature Reviews Urology 8:7, 385-392
CrossRef40
François Audenet, Elise Seringe, Sarah J. Drouin, Eva Comperat, Olivier Cussenot, Marc-Olivier Bitker, Morgan Rouprêt. (2011) Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World Journal of Urology
CrossRef41
Evanguelos Xylinas, Xavier Durand, Guillaume Ploussard, Alexandre Campeggi, Yves Allory, Dimitri Vordos, Andras Hoznek, Claude Clément Abbou, Alexandre de la Taille, Laurent Salomon. (2011) Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: Trifecta rate of achieving continence, potency and cancer control. Urologic Oncology: Seminars and Original Investigations
CrossRef42
Shunichi Namiki, Yoichi Arai. (2011) Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men. Reproductive Medicine and Biology 10:2, 59-68
CrossRef43
Amy T. Wang, Jeffrey K. Wang, Victor M. Montori, Mohammad Hassan Murad. (2011) Comparative effectiveness research in urology. World Journal of Urology 29:3, 277-282
CrossRef44
Holger Gerullis, Sonja Quast, Christoph Eimer, Jens W. Bagner, Thomas Otto. (2011) Sphincter Lesions After Radical Prostatectomy—Evaluation and Classification. Journal of Endourology 25:6, 1074-1079
CrossRef45
Rodolfo Montironi, Lars Egevad, Anders Bjartell, Daniel M. Berney. (2011) Role of histopathology and molecular markers in the active surveillance of prostate cancer. Acta Oncologica 50:S1, 56-60
CrossRef46
J.-A. Long, C. Thuillier, N. Terrier, J.-L. Descotes, J.-J. Rambeaud. (2011) Place de la prostatectomie radicale dans le traitement du cancer de prostate. Médecine Nucléaire 35:6, 384-389
CrossRef47
Daniel O'Brien, Stacy Loeb, Gustavo F. Carvalhal, Barry B. McGuire, Donghui Kan, Matthias D. Hofer, Jessica T. Casey, Brian T. Helfand, William J. Catalona. (2011) Delay of Surgery in Men With Low Risk Prostate Cancer. The Journal of Urology 185:6, 2143-2147
CrossRef48
Janet L. Colli. (2011) The effect of prostate cancer screening on stage IV disease in America. International Urology and Nephrology 43:2, 391-396
CrossRef49
Timothy J. Daskivich, Karim Chamie, Lorna Kwan, Jessica Labo, Roland Palvolgyi, Atreya Dash, Sheldon Greenfield, Mark S. Litwin. (2011) Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 117:10, 2058-2066
CrossRef50
Bill-Axelson, Anna, Holmberg, Lars, Ruutu, Mirja, Garmo, Hans, Stark, Jennifer R., Busch, Christer, Nordling, Stig, Häggman, Michael, Andersson, Swen-Olof, Bratell, Stefan, Spångberg, Anders, Palmgren, Juni, Steineck, Gunnar, Adami, Hans-Olov, Johansson, Jan-Erik, . (2011) Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer. New England Journal of Medicine 364:18, 1708-1717
Full Text51
Carvell T. Nguyen, J. Stephen Jones. (2011) Focal therapy in the management of localized prostate cancer. BJU International 107:9, 1362-1368
CrossRef52
Andreas Stensvold, Alv A. Dahl, Sophie D. Fosså, Karol Axcrona, Wolfgang Lilleby, Bjørn Brennhovd, Sigbjørn Smeland. (2011) Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center. Acta Oncologica 50:3, 408-414
CrossRef53
Sidney Glina. (2011) Erectile Dysfunction after Radical Prostatectomy. Drugs & Aging 28:4, 257-266
CrossRef54
David A Leavitt, Badrinath R Konety. (2011) Prostate-specific antigen screening in elderly men. Aging Health 7:2, 219-229
CrossRef55
Hugh J. Lavery, Adam W. Levinson, David B. Samadi. (2011) Robotic-assisted vs. open radical prostatectomy: When can we stop the debate?. Urologic Oncology: Seminars and Original Investigations
CrossRef56
Cristina Bosetti, Paola Bertuccio, Liliane Chatenoud, Eva Negri, Carlo La Vecchia, Fabio Levi. (2011) Trends in Mortality From Urologic Cancers in Europe, 1970???2008. European Urology
CrossRef57
Justin E. Bekelman, Anand Shah, Stephen M. Hahn. (2011) Implications of comparative effectiveness research for radiation oncology. Practical Radiation Oncology 1:2, 72-80
CrossRef58
Saleha Sajid, Supriya G. Mohile, Russell Szmulewitz, Edwin Posadas, William Dale. (2011) Individualized Decision-Making for Older Men With Prostate Cancer: Balancing Cancer Control With Treatment Consequences Across the Clinical Spectrum. Seminars in Oncology 38:2, 309-325
CrossRef59
Cole Davis, Matthew R. Cooperberg, Katsuto Shinohara, Peter R. Carroll. 2011. Rationale for Minimally Invasive Interventional Techniques in Urological Cancer. , 1-9.
CrossRef60
A. J. Vickers, C. Till, C. M. Tangen, H. Lilja, I. M. Thompson. (2011) An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection. JNCI Journal of the National Cancer Institute 103:6, 462-469
CrossRef61
Dragan Ilic, Denise O’Connor, Sally Green, Timothy J. Wilt. (2011) Screening for prostate cancer: an updated Cochrane systematic review. BJU International 107:6, 882-891
CrossRef62
Andrew Vickers, Caroline Savage, Fernando Bianco, John Mulhall, Jaspreet Sandhu, Bertrand Guillonneau, Angel Cronin, Peter Scardino. (2011) Cancer Control and Functional Outcomes After Radical Prostatectomy as Markers of Surgical Quality: Analysis of Heterogeneity Between Surgeons at a Single Cancer Center. European Urology 59:3, 317-322
CrossRef63
Osamu Ukimura, Andrew J Hung, Inderbir S Gill. (2011) Innovations in prostate biopsy strategies for active surveillance and focal therapy. Current Opinion in Urology 21:2, 115-120
CrossRef64
Ann S. Hamilton, Peter C. Albertsen, Terri Kang Johnson, Richard Hoffman, Donna Morrell, Dennis Deapen, David F. Penson. (2011) Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU International 107:4, 576-584
CrossRef65
Walter R. Parker, Rou Wang, Chang He, David P. Wood Jr. (2011) Five year Expanded Prostate cancer Index Composite-based quality of life outcomes after prostatectomy for localized prostate cancer. BJU International 107:4, 585-590
CrossRef66
Ian M. Thompson, Shady Salem, Sam S. Chang, Peter E. Clark, Rodney Davis, S. Duke Herrell, Yakup Kordan, Roxelyn Baumgartner, Sharon Phillips, Joseph A. Smith, Michael S. Cookson, Daniel A. Barocas. (2011) Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: A tale of two methods. World Journal of Urology 29:1, 15-20
CrossRef67
Petar Erdeljan, Gerald Brock, Stephen E. Pautler. (2011) Robot-Assisted Laparoscopic Prostatectomy in Patients with Preexisting Three-Piece Inflatable Penile Prosthesis. The Journal of Sexual Medicine 8:1, 306-309
CrossRef68
C. Stewart Rogers. (2011) Perspective on prostate cancer screening. International Journal of Clinical Practice 65:1, 31-34
CrossRef69
M. Andreas Røder, Kasper D. Berg, Lisa Gruschy, Klaus Brasso, Peter Iversen. (2011) First Danish Single-Institution Experience with Radical Prostatectomy: Biochemical Outcome in 1200 Consecutive Patients. Prostate Cancer 2011, 1-5
CrossRef70
C. Vaessen, M. Rouprêt. (2011) Apport potentiel de l’assistance robotisée dans le traitement chirurgical du cancer de prostate localisé. Oncologie 13:1, 25-28
CrossRef71
Axel Heidenreich, Joaquim Bellmunt, Michel Bolla, Steven Joniau, Malcolm Mason, Vsevolod Matveev, Nicolas Mottet, Hans-Peter Schmid, Theo van der Kwast, Thomas Wiegel, Filliberto Zattoni. (2011) EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. European Urology 59:1, 61-71
CrossRef72
Luigi Mearini, Massimo Porena. (2011) Pros and Cons of Focal Therapy for Localised Prostate Cancer. Prostate Cancer 2011, 1-8
CrossRef73
Michael Sinnott, Sara M. Falzarano, Adrian V. Hernandez, J. Stephen Jones, Eric A. Klein, Ming Zhou, Cristina Magi-Galluzzi. (2011) Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: Implications for focal therapy. The Prostaten/a-n/a
CrossRef74
Amitabh Chandra, David Cutler, Zirui Song. 2011. Who Ordered That? The Economics of Treatment Choices in Medical Care. , 397-432.
CrossRef75
Rafael F. Coelho, Bernardo Rocco, Manoj B. Patel, Marcelo A. Orvieto, Sanket Chauhan, Vincenzo Ficarra, Sara Melegari, Kenneth J. Palmer, Vipul R. Patel. (2010) Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: A Critical Review of Outcomes Reported by High-Volume Centers. Journal of Endourology 24:12, 2003-2015
CrossRef76
Mack Roach, Kyounghwa Bae, Colleen Lawton, B.J. Donnelly, David Grignon, Gerald E. Hanks, Arthur Porter, Herbert Lepor, Varagur Venketesan, Howard Sandler. (2010) Baseline Serum Testosterone in Men Treated With Androgen Deprivation Therapy and Radiotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 78:5, 1314-1322
CrossRef77
Mani Menon, Mahendra Bhandari, Nilesh Gupta, Zhaoli Lane, James O. Peabody, Craig G. Rogers, Jesse Sammon, Sameer A. Siddiqui, Mireya Diaz. (2010) Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy: Analysis of 1384 Patients with a Median 5-year Follow-up. European Urology 58:6, 838-846
CrossRef78
David S. Yoo, Terence Z. Wong, David M. Brizel. (2010) The Role of Adaptive and Functional Imaging Modalities in Radiation Therapy: Approach and Application from a Radiation Oncology Perspective. Seminars in Ultrasound, CT, and MRI 31:6, 444-461
CrossRef79
Chris O. Wambi, Sameer A. Siddiqui, L. Spencer Krane, Piyush K. Agarwal, Hans J. Stricker, James O. Peabody. (2010) Early oncological outcomes of robot-assisted radical prostatectomy for high-grade prostate cancer. BJU International 106:11, 1739-1745
CrossRef80
Marisa Warmuth, Tim Johansson, Philipp Mad. (2010) Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer. European Urology 58:6, 803-815
CrossRef81
J. Hadley, K. R. Yabroff, M. J. Barrett, D. F. Penson, C. S. Saigal, A. L. Potosky. (2010) Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data. JNCI Journal of the National Cancer Institute 102:23, 1780-1793
CrossRef82
Roman Ganzer, Andreas Blana. (2010) Do We Have Enough Evidence to Recommend the Routine Use of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer?. European Urology 58:6, 816-818
CrossRef83
Josephine Hegarty, Paul V Beirne, Ella Walsh, Harry Comber, Tony Fitzgerald, Meredith Wallace Kazer, Josephine Hegarty. 2010. Radical prostatectomy versus watchful waiting for prostate cancer. .
CrossRef84
Matthias Maruschke, Oliver W. Hakenberg. (2010) Probleme der PSA-Bestimmung bei älteren Patienten: was ist sinnvoll? / PSA measurements in elderly patients: what makes sense?. LaboratoriumsMedizin 34:6, 319-324
CrossRef85
John F. Ward. (2010) Prostate cancer: HIFU is effective, but associated morbidity still remains unclear. Nature Reviews Urology 7:11, 597-598
CrossRef86
Judd W. Moul. (2010) Editorial Comment. Urology 76:5, 1205
CrossRef87
Eva Compérat, Morgan Rouprêt, Sarah J. Drouin, Philippe Camparo, Marc-Olivier Bitker, Alain Houlgatte, Géraldine Cancel-Tassin, Olivier Cussenot. (2010) Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. The Prostate 70:15, 1622-1627
CrossRef88
Ping Tang, Leon Sun, Matthew A. Uhlman, Cary N. Robertson, Thomas J. Polascik, David M. Albala, Craig F. Donatucci, Judd W. Moul. (2010) Prostate-specific Antigen–based Risk-adapted Discontinuation of Prostate Cancer Screening in Elderly African American and Caucasian American Men. Urology 76:5, 1058-1062
CrossRef89
Matthias Maruschke, Oliver W. Hakenberg. (2010) PSA measurements in elderly patients: what makes sense? 1. LaboratoriumsMedizin 34:6, ---
CrossRef90
Johan Stranne, Eva Johansson, Andreas Nilsson, Anna Bill-Axelson, Stefan Carlsson, Lars Holmberg, Jan-Erik Johansson, Tommy Nyberg, Mirja Ruutu, N. Peter Wiklund, Gunnar Steineck. (2010) Inguinal Hernia After Radical Prostatectomy for Prostate Cancer: Results From a Randomized Setting and a Nonrandomized Setting. European Urology 58:5, 719-726
CrossRef91
Evanguelos Xylinas, Guillaume Ploussard, Xavier Durand, Alexandre de La Taille, Norman Gillion, Yves Allory, Dimitri Vordos, Andras Hoznek, Claude Clément Abbou, Laurent Salomon. (2010) Evaluation of Combined Oncological and Functional Outcomes After Radical Prostatectomy: Trifecta Rate of Achieving Continence, Potency and Cancer Control—A Literature Review. Urology 76:5, 1194-1198
CrossRef92
Giovanni Lughezzani, Alberto Briganti, Pierre I. Karakiewicz, Michael W. Kattan, Francesco Montorsi, Shahrokh F. Shariat, Andrew J. Vickers. (2010) Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. European Urology 58:5, 687-700
CrossRef93
F. Fiorica, M. Berretta, C. Colosimo, S. Berretta, M. Ristagno, T. Palmucci, S. Palmucci, A. Lleshi, S. Ursino, R. Fisichella, D. Spartà, A. Stefanelli, A. Cappellani, U. Tirelli, F. Cartei. (2010) Safety and efficacy of radiotherapy treatment in elderly patients with localized prostate cancer: A retrospective analysis. Archives of Gerontology and Geriatrics 51:3, 277-282
CrossRef94
Pim J. van Leeuwen, David Connolly, Teuvo L. J. Tammela, Anssi Auvinen, Ries Kranse, Monique J. Roobol, Fritz H. Schroder, Anna Gavin. (2010) Balancing the harms and benefits of early detection of prostate cancer. Cancer 116:20, 4857-4865
CrossRef95
Sarah J. Drouin, Eva Comperat, Olivier Cussenot, Marc-Olivier Bitker, Alain Haertig, Morgan Rouprêt. (2010) Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. Urologic Oncology: Seminars and Original Investigations
CrossRef96
M. Sugimoto, T. Shiraishi, H. Tsunemori, T. Demura, Y. Saito, T. Kamoto, Y. Kakehi. (2010) Pathological Findings at Radical Prostatectomy in Japanese Prospective Active Surveillance Cohort. Japanese Journal of Clinical Oncology 40:10, 973-979
CrossRef97
William M. Mendenhall, R. Charles Nichols, Randal Henderson, Nancy P. Mendenhall. (2010) Is Radical Prostatectomy the “Gold Standard” for Localized Prostate Cancer?. American Journal of Clinical Oncology 33:5, 511-515
CrossRef98
Emilie Lecornet, Caroline Moore, Hashim Uddin Ahmed, Mark Emberton. (2010) Focal therapy for prostate cancer: Fact or fiction?. Urologic Oncology: Seminars and Original Investigations 28:5, 550-556
CrossRef99
Mara S. Meyer, Lorelei A. Mucci, Swen-Olof Andersson, Ove Andrén, Jan-Erik Johansson, Steinar Tretli, Hans-Olov Adami. (2010) Homogeneous Prostate Cancer Mortality in the Nordic Countries Over Four Decades. European Urology 58:3, 427-432
CrossRef100
Taekmin Kwon, In Gab Jeong, Dalsan You, Myung-Chan Park, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim. (2010) Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level?. BJU International 106:5, 633-638
CrossRef101
Stacy Loeb, Gustavo F. Carvalhal, Donghui Kan, Angel Desai, William J. Catalona. (2010) External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urologic Oncology: Seminars and Original Investigations
CrossRef102
David I. Chu, Stephen J. Freedland. (2010) Prostate cancer: Socioeconomic status and disparities in treatment patterns. Nature Reviews Urology 7:9, 480-481
CrossRef103
Angelish Kumar, Victor W. Nitti. (2010) Contemporary Incidence of Postprostatectomy Incontinence and Impact on Health-related Quality of Life. Current Bladder Dysfunction Reports 5:3, 135-141
CrossRef104
Vipul R. Patel, Rafael F. Coelho, Sanket Chauhan, Marcelo A. Orvieto, Kenneth J. Palmer, Bernardo Rocco, Ananthakrishnan Sivaraman, Geoff Coughlin. (2010) Continence, potency and oncological outcomes after robotic-assisted radical prostatectomy: early trifecta results of a high-volume surgeon. BJU International 106:5, 696-702
CrossRef105
A-E. Carsin, F. J. Drummond, A. Black, P. J. Leeuwen, L. Sharp, L. J. Murray, D. Connolly, L. Egevad, M. Boniol, P. Autier, H. Comber, A. Gavin. (2010) Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes & Control 21:9, 1523-1531
CrossRef106
R. Kvåle, B. Møller, A. Angelsen, O. Dahl, S.D. Fosså, O.J. Halvorsen, L. Hoem, A. Solberg, R. Wahlqvist, F. Bray. (2010) Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiology 34:4, 359-367
CrossRef107
S.-L. Yao, G. L. Lu-Yao. (2010) Diagnosis of Localized, Screen-Detected, Prostate Cancer--Crisis or Opportunity?. JNCI Journal of the National Cancer Institute 102:13, 919-920
CrossRef108
Hendrik Isbarn, Manuela Wanner, Georg Salomon, Thomas Steuber, Thorsten Schlomm, Jens Köllermann, Guido Sauter, Alexander Haese, Hans Heinzer, Hartwig Huland, Markus Graefen. (2010) Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU International 106:1, 37-43
CrossRef109
Michael C. Lee, Fei Dong, Andrew J. Stephenson, J. Stephen Jones, Cristina Magi-Galluzzi, Eric A. Klein. (2010) The Epstein Criteria Predict for Organ-Confined But Not Insignificant Disease and a High Likelihood of Cure at Radical Prostatectomy. European Urology 58:1, 90-95
CrossRef110
Uri Lindner, Nathan Lawrentschuk, Robert A. Weersink, Orit Raz, Eugen Hlasny, Marshall S. Sussman, Sean R. Davidson, Mark R. Gertner, John Trachtenberg. (2010) Construction and Evaluation of an Anatomically Correct Multi-Image Modality Compatible Phantom for Prostate Cancer Focal Ablation. The Journal of Urology 184:1, 352-357
CrossRef111
Daniel A. Barocas, Michael S. Cookson. 2010. Surgical Management of Clinically Localized Prostate Cancer. , 255-266.
CrossRef112
Philipp Dahm, Holger J. Schünemann. 2010. Rating the Quality of Evidence and Making Recommendations. , 29-37.
CrossRef113
Karen E. Hoffman, Ming-Hui Chen, Brian J. Moran, Michelle H. Braccioforte, Daniel Dosoretz, Sharon Salenius, Michael J. Katin, Rudi Ross, Anthony V. D'Amico. (2010) Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 116:11, 2590-2595
CrossRef114
Rafael F. Coelho, Kenneth J. Palmer, Bernardo Rocco, Ravendra R. Moniz, Sanket Chauhan, Marcelo A. Orvieto, Geoff Coughlin, Vipul R. Patel. (2010) Early Complication Rates in a Single-Surgeon Series of 2500 Robotic-Assisted Radical Prostatectomies: Report Applying a Standardized Grading System. European Urology 57:6, 945-952
CrossRef115
C. La Vecchia, C. Bosetti, F. Lucchini, P. Bertuccio, E. Negri, P. Boyle, F. Levi. (2010) Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology 21:6, 1323-1360
CrossRef116
Jonathan L. Wright, Bruce L. Dalkin, Lawrence D. True, William J. Ellis, Janet L. Stanford, Paul H. Lange, Daniel W. Lin. (2010) Positive Surgical Margins at Radical Prostatectomy Predict Prostate Cancer Specific Mortality. The Journal of Urology 183:6, 2213-2218
CrossRef117
E D Crawford, L Black, M Eaddy, E J Kruep. (2010) A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer and Prostatic Diseases 13:2, 162-167
CrossRef118
Roger Kirby, Kate Holmes, Peter Amoroso. (2010) SUPPORTING THE SUPPORTER: HELPING THE PARTNER OF PATIENTS NEWLY DIAGNOSED WITH PROSTATE CANCER. BJU International 105:11, 1489-1490
CrossRef119
Emilie Lecornet, Hashim Uddin Ahmed, Caroline M. Moore, Mark Emberton. (2010) Conceptual Basis for Focal Therapy in Prostate Cancer. Journal of Endourology 24:5, 811-818
CrossRef120
J. Boddy, N. Lai, C. Lynch, S.A. Shahzad, A.P. Doherty, D.M.A. Wallace, R.I. Bhatt. (2010) The role of active surveillance in the management of early prostate cancer and the impact of the NICE guidelines. British Journal of Medical and Surgical Urology 3:3, 101-105
CrossRef121
Laurence Klotz. (2010) Active Surveillance for Prostate Cancer: A Review. Current Urology Reports 11:3, 165-171
CrossRef122
Roger Kirby, Kate Holmes, Peter Amoroso. (2010) Supporting the supporter: helping the partner of patients newly diagnosed with prostate cancer. BJU Internationalno-no
CrossRef123
Jeffrey Rochelle, Christopher L. Amling. (2010) Prostate Cancer Screening: What We Have Learned from the PLCO and ERSPC Trials. Current Urology Reports 11:3, 198-201
CrossRef124
Jorge R. Caso, Vladimir Mouraviev, Matvey Tsivian, Thomas J. Polascik, Judd W. Moul. (2010) Prostate Cancer: An Evolving Paradigm. Journal of Endourology 24:5, 805-809
CrossRef125
Hans-Olov Adami. (2010) The prostate cancer pseudo-epidemic. Acta Oncologica 49:3, 298-304
CrossRef126
Danil V. Makarov, Stacy Loeb, Adam B. Landman, Matthew E. Nielsen, Cary P. Gross, Douglas L. Leslie, David F. Penson, Rani A. Desai. (2010) Regional Variation in Total Cost per Radical Prostatectomy in the Healthcare Cost and Utilization Project Nationwide Inpatient Sample Database. The Journal of Urology 183:4, 1504-1509
CrossRef127
Andrea Gallina. (2010) Editorial Comment on: Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer. European Urology 57:4, 639
CrossRef128
Daniel A. Barocas, Shady Salem, Yakup Kordan, S. Duke Herrell, Sam S. Chang, Peter E. Clark, Rodney Davis, Roxelyn Baumgartner, Sharon Phillips, Michael S. Cookson, Joseph A. Smith. (2010) Robotic Assisted Laparoscopic Prostatectomy Versus Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer: Comparison of Short-Term Biochemical Recurrence-Free Survival. The Journal of Urology 183:3, 990-996
CrossRef129
Peter L. Steinberg, Shaun Wason, Joshua M. Stern, Levi Deters, Brian Kowal, John Seigne. (2010) YouTube as Source of Prostate Cancer Information. Urology 75:3, 619-622
CrossRef130
Fernando J. Bianco, Andrew J. Vickers, Angel M. Cronin, Eric A. Klein, James A. Eastham, J. Edson Pontes, Peter T. Scardino. (2010) Variations Among Experienced Surgeons in Cancer Control After Open Radical Prostatectomy. The Journal of Urology 183:3, 977-983
CrossRef131
Kate Tilling, Hans Garmo, Chris Metcalfe, Lars Holmberg, Freddie C. Hamdy, David E. Neal, Jan Adolfsson, Richard M. Martin, Michael Davis, Katja Fall, J. Athene Lane, Hans-Olaf Adami, Anna Bill-Axelson, Jan-Eric Johansson, Jenny L. Donovan. (2010) Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. European Urology 57:3, 446-452
CrossRef132
Oliver Sartor, David G. McLeod, Susan Halabi, Paul F. Schellhammer, Peter T. Scardino, Anthony V. D'Amico, Charles Bennett, John T. Wei. (2010) The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer. Urology 75:3, 623-629
CrossRef133
Neil E. Fleshner, Andrew Evans, Karen Chadwick, Nathan Lawrentschuk, Alexandre Zlotta. (2010) Clinical significance of the positive surgical margin based upon location, grade, and stage. Urologic Oncology: Seminars and Original Investigations 28:2, 197-204
CrossRef134
M.-O. Grimm, C. Thomas, M. Fröhner, T. Wiegel, A. Heidenreich, J.W. Thüroff, M. Wirth. (2010) Pelvine Lymphadenektomie und radikale Prostatektomie. Der Urologe 49:2, 206-210
CrossRef135
Shunichi Namiki, Yoichi Arai. (2010) Health-related quality of life in men with localized prostate cancer. International Journal of Urology 17:2, 125-138
CrossRef136
L. Weißbach, C. Schaefer, A. Heidenreich. (2010) Ein Paradigmenwechsel. Der Urologe 49:2, 199-205
CrossRef137
Hashim U Ahmed, Mark Emberton. (2010) Is focal therapy the future for prostate cancer?. Future Oncology 6:2, 261-268
CrossRef138
Eric C. Umbreit, Eric J. Dozois, Paul L. Crispen, Matthew K. Tollefson, R. Jeffrey Karnes, Michael L. Blute. (2010) Radical Prostatectomy for Prostate Cancer after Ileal Pouch-Anal Anastomosis Offers Oncologic Control and Sustains Quality of Life. Journal of the American College of Surgeons 210:2, 232-239
CrossRef139
Bryan J. Donnelly, John C. Saliken, Penelope M. A. Brasher, Scott D. Ernst, John C. Rewcastle, Harold Lau, John Robinson, Kiril Trpkov. (2010) A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 116:2, 323-330
CrossRef140
J. Gulcher, K. Stefansson. (2010) Genetic risk information for common diseases may indeed be already useful for prevention and early detection. European Journal of Clinical Investigation 40:1, 56-63
CrossRef141
Sultan Alkhateeb, Shabbir Alibhai, Neil Fleshner, Antonio Finelli, Michael Jewett, Alexandre Zlotta, Michael Nesbitt, Gina Lockwood, John Trachtenberg. (2010) Impact of Positive Surgical Margins After Radical Prostatectomy Differs by Disease Risk Group. The Journal of Urology 183:1, 145-150
CrossRef142
Pim J. van Leeuwen, David Connolly, Anna Gavin, Monique J. Roobol, Amanda Black, Chris H. Bangma, Fritz H. Schröder. (2010) Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. European Journal of Cancer 46:2, 377-383
CrossRef143
Nicolas Doumerc, Carlo Yuen, Richard Savdie, Md. Bayzidur Rahman, Ruth Pe Benito, Phillip Stricker. (2010) Robot-assisted laparoscopic prostatectomy: analysis of an experienced open surgeon’s learning curve after 300 procedures. Journal of Robotic Surgery 3:4, 229-234
CrossRef144
Mitchell C. Benson. (2010) Editorial Comment. The Journal of Urology 183:1, 131
CrossRef145
R. J. Karnes, T. Hatano, M. L. Blute, R. P. Myers. (2010) Radical Prostatectomy for High-risk Prostate Cancer. Japanese Journal of Clinical Oncology 40:1, 3-9
CrossRef146
X. Maldonado, G. Sancho, M. Ferrer, F. Guedea. (2010) Critical review of the use of radiotherapy as initial treatment of localized prostate cancer. Actas Urológicas Españolas (English Edition) 34:5, 401-402
CrossRef147
J. Rubio-Briones, I. Iborra, M. Trassierra, A. Collado, J. Casanova, A. Gómez-Ferrer, J.V. Ricós, J.L. Monrós, R. Dumont, E. Solsona. (2010) Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy. Actas Urológicas Españolas (English Edition) 34:7, 610-617
CrossRef148
E. Morán Pascual, C. Dicapua Sacoto, M. Trassierra Villa, J.L. Pontones Moreno, J.L. Ruiz Cerdá, J.F. Jiménez Cruz. (2010) Watchful waiting in incidental adenocarcinoma of the prostate. Actas Urológicas Españolas (English Edition) 34:10, 854-859
CrossRef149
Alison L. Moore, Polyxeni Dimitropoulou, Athene Lane, Philip H. Powell, David C. Greenberg, Clement H. Brown, Jenny L. Donovan, Freddie C. Hamdy, Richard M. Martin, David E. Neal. (2009) Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU International 104:11, 1592-1598
CrossRef150
Nicholas J. van As, Nandita M. de Souza, Sophie F. Riches, Veronica A. Morgan, Sayid A. Sohaib, David P. Dearnaley, Chris C. Parker. (2009) A Study of Diffusion-Weighted Magnetic Resonance Imaging in Men with Untreated Localised Prostate Cancer on Active Surveillance. European Urology 56:6, 981-988
CrossRef151
Laurence Klotz. (2009) Active Surveillance for Favorable Risk Prostate Cancer. The Journal of Urology 182:6, 2565-2566
CrossRef152
Krishna Patil, Roger Kirby, James Hicks, Jens-Uwe Stolzenburg. (2009) LAPAROSCOPY OR ROBOTICS: WHERE DOES THE FUTURE LIE?. BJU International 104:11, 1551-1553
CrossRef153
L Fairley, M Baker, J Whiteway, W Cross, D Forman. (2009) Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000–2006. British Journal of Cancer 101:11, 1839-1845
CrossRef154
Hans Heinzer, Thomas Steuber. (2009) Prostate cancer in the elderly. Urologic Oncology: Seminars and Original Investigations 27:6, 668-672
CrossRef155
Kirsten L. Greene, Peter C. Albertsen, Richard J. Babaian, H. Ballentine Carter, Peter H. Gann, Misop Han, Deborah Ann Kuban, A. Oliver Sartor, Janet L. Stanford, Anthony Zietman, Peter Carroll. (2009) Prostate Specific Antigen Best Practice Statement: 2009 Update. The Journal of Urology 182:5, 2232-2241
CrossRef156
Mark Soloway. (2009) Low-risk prostate cancer and low testosterone: What are the acceptable alternatives?. Current Urology Reports 10:6, 413-417
CrossRef157
Rafael F. Coelho, Sanket Chauhan, Kenneth J. Palmer, Bernardo Rocco, Manoj B. Patel, Vipul R. Patel. (2009) Robotic-assisted radical prostatectomy: a review of current outcomes. BJU International 104:10, 1428-1435
CrossRef158
O. W. Brawley. (2009) Prostate Cancer Screening; Is This a Teachable Moment?. JNCI Journal of the National Cancer Institute 101:19, 1295-1297
CrossRef159
C S Foster, A R Dodson, L Ambroisine, G Fisher, H Møller, J Clark, G Attard, J De-Bono, P Scardino, V E Reuter, C S Cooper, D M Berney, J Cuzick. (2009) Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. British Journal of Cancer 101:7, 1137-1144
CrossRef160
Jesco Pfitzenmaier, Sascha Pahernik, Stephan Buse, Axel Haferkamp, Nenad Djakovic, Markus Hohenfellner. (2009) Survival in prostate cancer patients ≥70 years after radical prostatectomy and comparison to younger patients. World Journal of Urology 27:5, 637-642
CrossRef161
Yu-Ning Wong, Stephen J. Freedland, Brian Egleston, Neha Vapiwala, Robert Uzzo, Katrina Armstrong. (2009) The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer. European Urology 56:4, 609-616
CrossRef162
Sarah J. Drouin, Christophe Vaessen, Vincent Hupertan, Eva Comperat, Vincent Misraï, Alain Haertig, Marc-Olivier Bitker, Emmanuel Chartier-Kastler, François Richard, Morgan Rouprêt. (2009) Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robot-assisted radical prostatectomy for localized prostate cancer. World Journal of Urology 27:5, 599-605
CrossRef163
I. L. Savetsky, F. Rabbani, K. Singh, M. S. Brady. (2009) Preperitoneal repair of inguinal hernia at open radical prostatectomy. Hernia 13:5, 517-522
CrossRef164
Shunichi Namiki, Shigeto Ishidoya, Tatsuo Tochigi, Akihiro Ito, Yoichi Arai. (2009) Quality of life after radical prostatectomy in elderly men. International Journal of Urology 16:10, 813-819
CrossRef165
Kien Nguyen, Stephanie Eltz, Sarah J. Drouin, Eva Comperat, François Audenet, Raphaele Renard-Penna, Marc-Olivier Bitker, Emmanuel Chartier-Kastler, François Richard, Olivier Cussenot, Morgan Rouprêt. (2009) Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. World Journal of Urology 27:5, 653-658
CrossRef166
Y.-H. Shao, K. Demissie, W. Shih, A. R. Mehta, M. N. Stein, C. B. Roberts, R. S. DiPaola, G. L. Lu-Yao. (2009) Contemporary Risk Profile of Prostate Cancer in the United States. JNCI Journal of the National Cancer Institute 101:18, 1280-1283
CrossRef167
Russell N. Moule, Peter J. Hoskin. (2009) Non-surgical treatment of localised prostate cancer. Surgical Oncology 18:3, 255-267
CrossRef168
D Wittmann, J E Montie, D A Hamstra, H Sandler, D P Wood. (2009) Counseling patients about sexual health when considering post-prostatectomy radiation treatment. International Journal of Impotence Research 21:5, 275-284
CrossRef169
Hashim Uddin Ahmed, Caroline Moore, Mark Emberton. (2009) Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surgical Oncology 18:3, 219-232
CrossRef170
Raanan Tal, Hannah H. Alphs, Paul Krebs, Christian J. Nelson, John P. Mulhall. (2009) Erectile Function Recovery Rate after Radical Prostatectomy: A Meta-Analysis. Journal of Sexual Medicine 6:9, 2538-2546
CrossRef171
Shailesh Singh, Rajesh Singh, Praveen K. Sharma, Udai P Singh, Shesh N. Rai, Leland W.K. Chung, Carlton R. Cooper, Kristian R. Novakovic, William E. Grizzle, James W. Lillard. (2009) Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Letters 283:1, 29-35
CrossRef172
Stefania Sciallero, Giuseppe Fornarini. (2009) Prostate cancer screening with PSA: new data, old debate. Oncology Reviews 3:3, 133-135
CrossRef173
Morgan Rouprêt, Vincent Hupertan, Eva Comperat, Sarah J. Drouin, Véronique Phé, Evanguelos Xylinas, David Demanse, Mathilde Sibony, Francois Richard, Olivier Cussenot. (2009) Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy. BJU International 104:6, 813-818
CrossRef174
C Metcalfe, K Tilling, M Davis, J A Lane, R M Martin, H Kynaston, P Powell, D E Neal, F Hamdy, J L Donovan. (2009) Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. British Journal of Cancer 101:3, 390-394
CrossRef175
Ahmed Magheli, Arthur L. Burnett. (2009) Erectile dysfunction following prostatectomy: prevention and treatment. Nature Reviews Urology 6:8, 415-427
CrossRef176
Brian A. Parsons, Simon Evans, Mark P. Wright. (2009) Prostate cancer and urinary incontinence. Maturitas 63:4, 323-328
CrossRef177
H U Ahmed, E Zacharakis, T Dudderidge, J N Armitage, R Scott, J Calleary, R Illing, A Kirkham, A Freeman, C Ogden, C Allen, M Emberton. (2009) High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. British Journal of Cancer 101:1, 19-26
CrossRef178
Karim Touijer, Peter T. Scardino. (2009) Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer 115:S13, 3107-3111
CrossRef179
Maria Michela Gianino, Mario Galzerano, Davide Minniti, Cinzia Di Novi, Barbara Martin, Ottavio Davini, Silvana Barbaro. (2009) A comparative costs analysis of brachytherapy and Radical Retropubic Prostatectomy therapies for clinically localized prostate cancer. International Journal of Technology Assessment in Health Care 25:03, 411
CrossRef180
Ferran Guedea, Montse Ferrer. (2009) Spanish Researchers at the Forefront of Clinical Investigation: The case of quality of life in prostate cancer. Clinical and Translational Oncology 11:7, 403-404
CrossRef181
Nadine Coull, Alan Thompson. (2009) Treatment of early prostate cancer: radical prostatectomy. Trends in Urology, Gynaecology & Sexual Health 14:4, 10-15
CrossRef182
Gerald Y Tan, Youssef El Douaihy, Alexis E Te, Ashutosh K Tewari. (2009) Scientific and technical advances in continence recovery following radical prostatectomy. Expert Review of Medical Devices 6:4, 431-453
CrossRef183
Lars Holmberg. (2009) Prostate Cancer Screening: The Need For Problem-Solving that Puts Men's Interests First. European Urology 56:1, 34-37
CrossRef184
Michael J. Donovan, Faisal M. Khan, Gerardo Fernandez, Ricardo Mesa-Tejada, Marina Sapir, Valentina Bayer Zubek, Douglas Powell, Stephen Fogarasi, Yevgen Vengrenyuk, Mikhail Teverovskiy, Mark R. Segal, R. Jeffrey Karnes, Thomas A. Gaffey, Christer Busch, Michael Haggman, Peter Hlavcak, Stephen J. Freedland, Robin T. Vollmer, Peter Albertsen, Jose Costa, Carlos Cordon-Cardo. (2009) Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy. The Journal of Urology 182:1, 125-132
CrossRef185
Roderick C.N. van den Bergh, Stijn Roemeling, Monique J. Roobol, Gunnar Aus, Jonas Hugosson, Antti S. Rannikko, Teuvo L. Tammela, Chris H. Bangma, Fritz H. Schröder. (2009) Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU International 103:11, 1472-1477
CrossRef186
S Jhavar, J Bartlett, G Kovacs, C Corbishley, D Dearnaley, R Eeles, V Khoo, R Huddart, A Horwich, A Thompson, A Norman, D Brewer, C S Cooper, C Parker. (2009) Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer and Prostatic Diseases 12:2, 143-147
CrossRef187
Chad R. Ritch, Aaron E. Katz. (2009) Update on cryotherapy for localized prostate cancer. Current Urology Reports 10:3, 206-211
CrossRef188
Peiguo G. Chu, Sean K. Lau, Lawrence M. Weiss, Mark Kawachi, Jeffrey Yoshida, Christopher Ruel, Rebecca Nelson, Laura Crocitto, Timothy Wilson. (2009) Assessment of low prostate weight as a determinant of a higher positive margin rate after laparoscopic radical prostatectomy: a prospective pathologic study of 1,500 cases. Surgical Endoscopy 23:5, 1058-1064
CrossRef189
Ryan K. Berglund, Andrew J. Stephenson, Angel M. Cronin, Andrew J. Vickers, James A. Eastham, Eric A. Klein, Bertrand D. Guillonneau. (2009) Comparison of Observed Biochemical Recurrence-free Survival in Patients With Low PSA Values Undergoing Radical Prostatectomy and Predictions of Preoperative Nomogram. Urology 73:5, 1098-1103
CrossRef190
Leonard G. Gomella, James Johannes, Edouard J. Trabulsi. (2009) Current Prostate Cancer Treatments: Effect on Quality of Life. Urology 73:5, S28-S35
CrossRef191
A. Horwich, C. Parker, V. Kataja, . (2009) Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv76-iv78
CrossRef192
David J Galvin, James A Eastham. (2009) Critical appraisal of outcomes following open radical prostatectomy. Current Opinion in Urology 19:3, 297-302
CrossRef193
Patrick C. Walsh. (2009) 2008 Whitmore Lecture: Radical prostatectomy—where we were and where we are going. Urologic Oncology: Seminars and Original Investigations 27:3, 246-250
CrossRef194
Helen O'Donnell, Chris Parker. (2009) Treatment of early prostate cancer: active surveillance. Trends in Urology, Gynaecology & Sexual Health 14:3, 15-19
CrossRef195
Per-Anders Abrahamsson. (2009) Prostate Cancer: To Treat or Not to Treat?. European Urology Supplements 8:5, 418-423
CrossRef196
Jesse N. Aronowitz. (2009) “Benign Essential” Prostate Cancer?. American Journal of Clinical Oncology 32:2, 224-225
CrossRef197
Hashim U. Ahmed, Alex Kirkham, Manit Arya, Rowland Illing, Alex Freeman, Clare Allen, Mark Emberton. (2009) Is it time to consider a role for MRI before prostate biopsy?. Nature Reviews Clinical Oncology 6:4, 197-206
CrossRef198
Andriole, Gerald L., Crawford, E. David, Grubb, Robert L. III, Buys, Saundra S., Chia, David, Church, Timothy R., Fouad, Mona N., Gelmann, Edward P., Kvale, Paul A., Reding, Douglas J., Weissfeld, Joel L., Yokochi, Lance A., O'Brien, Barbara, Clapp, Jonathan D., Rathmell, Joshua M., Riley, Thomas L., Hayes, Richard B., Kramer, Barnett S., Izmirlian, Grant, Miller, Anthony B., Pinsky, Paul F., Prorok, Philip C., Gohagan, John K., Berg, Christine D., . (2009) Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine 360:13, 1310-1319
Full Text199
Chad R Ritch, Aaron E Katz. (2009) Prostate cryotherapy: current status. Current Opinion in Urology 19:2, 177-181
CrossRef200
R Tim D Oliver, David E Neal. (2009) Treatment for PSA screen-detected prostate cancer: what are the options?. Nature Clinical Practice Urology 6:3, 132-134
CrossRef201
Michael Froehner, Rainer Koch, Rainer J. Litz, Manfred P. Wirth. (2009) Nomogram Underestimates 10-year Survival in Healthy Men Selected for Radical Prostatectomy at Age 70 Years or Older. Urology 73:3, 610-613
CrossRef202
David W McDermott, Martin G Sanda. (2009) Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4. Nature Clinical Practice Urology 6:3, 124-125
CrossRef203
Prokar Dasgupta, Roger S Kirby. (2009) Outcomes of robotic assisted radical prostatectomy. International Journal of Urology 16:3, 244-248
CrossRef204
Ian M. Thompson, Catherine M. Tangen, Jorge Paradelo, M. Scott Lucia, Gary Miller, Dean Troyer, Edward Messing, Jeffrey Forman, Joseph Chin, Gregory Swanson, Edith Canby-Hagino, E. David Crawford. (2009) Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. The Journal of Urology 181:3, 956-962
CrossRef205
Melina Gattellari, Jeanette E. Ward. (2009) Editorial Comment on: Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial. European Urology 55:2, 431
CrossRef206
Eva Johansson, Anna Bill-Axelson, Lars Holmberg, Erik Onelöv, Jan-Erik Johansson, Gunnar Steineck. (2009) Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial. European Urology 55:2, 422-432
CrossRef207
Shahrokh F. Shariat, Umberto Capitanio, Claudio Jeldres, Pierre I. Karakiewicz. (2009) Can nomograms be superior to other prediction tools?. BJU International 103:4, 492-497
CrossRef208
Marc A. Dall’Era, Christopher J. Kane. (2009) Watchful waiting versus active surveillance: Appropriate patient selection. Current Prostate Reports 7:1, 5-10
CrossRef209
R. J. Schulz, A. R. Kagan. (2009) Re: Prostatectomy vs Watchful Waiting in Localized Prostate Cancer: The Scandinavian Prostate Cancer Group-4 Randomized Trial. JNCI Journal of the National Cancer Institute 101:2, 124-124
CrossRef210
Declan G. Murphy, Benjamin J. Challacombe, Anthony J. Costello. (2009) Outcomes after robot-assisted laparoscopic radical prostatectomy. Asian Journal of Andrology 11:1, 94-99
CrossRef211
Roger Kirby, Shu-Jie Xia. (2009) Editorial and introduction to Asian Journal of Andrology Prostate Cancer special issue. Asian Journal of Andrology 11:1, 6-8
CrossRef212
Sigrid Carlsson, Jan Adolfsson, Ola Bratt, Jan-Erik Johansson, Christer Ahlstrand, Erik Holmberg, Pär Stattin, Jonas Hugosson. (2009) Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scandinavian Journal of Urology and Nephrology 43:5, 350-356
CrossRef213
Stephan Madersbacher, Anton Ponholzer. (2009) Re: Fleur I. de Korte, Jochem W. van Werkum, Peter L.M. Vijverberg, Jurriën M. ten Berg. Late Coronary Stent Thrombosis Complicating Urologic Surgery. Eur Urol 2008;54:221–5. European Urology 55:1, e27-e28
CrossRef214
Prokar Dasgupta, Roger S. Kirby. (2009) The current status of robot-assisted radical prostatectomy. Asian Journal of Andrology 11:1, 90-93
CrossRef215
Roderick C.N. van den Bergh, Stijn Roemeling, Monique J. Roobol, Gunnar Aus, Jonas Hugosson, Antti S. Rannikko, Teuvo L. Tammela, Chris H. Bangma, Fritz H. Schröder. (2009) Platinum Priority – Reply from Authors re: Peter C. Albertsen. The Treatment Paradigm Shifts Again on Prostate Cancer. Eur Urol 2009;55:9–11. European Urology 55:1, 11-13
CrossRef216
Esther H. Zhou, Rodney J. Ellis, Edward Cherullo, Valdir Colussi, Fang Xu, Wei-Dong Chen, Sanjay Gupta, Christopher C. Whalen, Donald Bodner, Martin I. Resnick, Alfred A. Rimm, Siran M. Koroukian. (2009) Radiotherapy and Survival in Prostate Cancer Patients: A Population-Based Study. International Journal of Radiation Oncology*Biology*Physics 73:1, 15-23
CrossRef217
Taek Sang Kim, Su Hwan Kang, Hyun Yul Rhew. (2009) Efficacy of Androgen Deprivation Therapy in Patients with Clinically Localized Prostate Cancer. Korean Journal of Urology 50:11, 1073
CrossRef218
Vibha Bhatnagar, Dominick L. Frosch, Steven R. Tally, Charles J. Hamori, Leslie Lenert, Robert M. Kaplan. (2009) Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening. Value in Health 12:1, 101-108
CrossRef219
Claudia I. Henschke, Rowena Yip, David F. Yankelevitz. (2009) CT Screening for Lung Cancer: Update 2008. Haigan 49:4, 477-490
CrossRef220
John Concato. (2009) What Will the Emperor Say?. The Cancer Journal 15:1, 7-12
CrossRef221
(2008) Management of Prostate Cancer. New England Journal of Medicine 359:24, 2605-2609
Full Text222
Nicholas J. van As, Andrew R. Norman, Karen Thomas, Vincent S. Khoo, Alan Thompson, Robert A. Huddart, Alan Horwich, David P. Dearnaley, Christopher C. Parker. (2008) Predicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer Managed by Active Surveillance. European Urology 54:6, 1297-1305
CrossRef223
Supriya G. Mohile, Mark Lachs, William Dale. (2008) Management of Prostate Cancer in the Older Man. Seminars in Oncology 35:6, 597-617
CrossRef224
David F. Penson, Michel Rossignol, A. Oliver Sartor, Peter T. Scardino, Lucien L. Abenhaim. (2008) Prostate Cancer: Epidemiology and Health-related Quality of Life. Urology 72:6, S3-S11
CrossRef225
Grace Lu-Yao, Peter C. Albertsen, Janet L. Stanford, Therese A. Stukel, Elizabeth Walker-Corkery, Michael J. Barry. (2008) Screening, Treatment, and Prostate Cancer Mortality in the Seattle Area and Connecticut: Fifteen-year Follow-up. Journal of General Internal Medicine 23:11, 1809-1814
CrossRef226
R.-J. Palisaar, J. Noldus. (2008) Stellenwert der radikalen Prostatektomie beim lokal fortgeschrittenen Prostatakarzinom. Der Urologe 47:11, 1417-1423
CrossRef227
Scott T. Tagawa, Tanya B. Dorff, Leanne Rochanda, Wei Ye, Soames Boyle, Derek Raghavan, Gary Lieskovsky, Donald G. Skinner, David I. Quinn, Howard A. Liebman. (2008) Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU International 102:9, 1086-1091
CrossRef228
Ryan K. Berglund, Timothy A. Masterson, Kinjal C. Vora, Scott E. Eggener, James A. Eastham, Bertrand D. Guillonneau. (2008) Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active Surveillance. The Journal of Urology 180:5, 1964-1968
CrossRef229
Arne Berg, Øyvind S. Bruland, Sophie D. Fosså, Jahn M. Nesland, Aasmund Berner, Cecilie Schirmer, Wolfgang Lilleby. (2008) Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. The Prostate 68:15, 1607-1614
CrossRef230
(2008) Response to the Letter by Dr. Marshall. The American Journal of Gastroenterology 103:11, 2940-2940
CrossRef231
Guan Xu, Daqing Piao, Cameron H. Musgrove, Charles F. Bunting, Hamid Dehghani. (2008) Trans-rectal ultrasound-coupled near-infrared optical tomography of the prostate, Part I: Simulation. Optics Express 16:22, 17484
CrossRef232
Benjamin D. Sommers, Clair J. Beard, Anthony V. D'Amico, Irving Kaplan, Jerome P. Richie, Richard J. Zeckhauser. (2008) Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113:8, 2058-2067
CrossRef233
John Anderson, Cora N. Sternberg. (2008) Adapting treatment for prostate cancer according to risk of disease progression. Critical Reviews in Oncology/Hematology 68:1, S23-S31
CrossRef234
Gregory S. Merrick, Kent E. Wallner, Robert W. Galbreath, Wayne M. Butler, Sarah G. Brammer, Zachariah A. Allen, Edward Adamovich. (2008) Prostate Brachytherapy in Men ≥75 Years of Age. International Journal of Radiation Oncology*Biology*Physics 72:2, 415-420
CrossRef235
Laurence Klotz. (2008) Active surveillance for prostate cancer: trials and tribulations. World Journal of Urology 26:5, 437-442
CrossRef236
Helen O’Donnell, Chris Parker. (2008) What is low-risk prostate cancer and what is its natural history?. World Journal of Urology 26:5, 415-422
CrossRef237
William M. Mendenhall, Randal H. Henderson, Nancy P. Mendenhall. (2008) Definitive Radiotherapy for Prostate Cancer. American Journal of Clinical Oncology 31:5, 496-503
CrossRef238
Hashim Uddin Ahmed, Mark Emberton. (2008) Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?. World Journal of Urology 26:5, 457-467
CrossRef239
Shandra W Wilson. (2008) Screening for prostate cancer in the aging population: current and future trends. Aging Health 4:5, 463-467
CrossRef240
Simon F. Brewster. (2008) LOW-RISK LOCALIZED PROSTATE CANCER: ARE WE READY TO TELL PATIENTS THAT ACTIVE SURVEILLANCE IS THE PREFERRED OPTION?. BJU International 102:8, 923-926
CrossRef241
Judd W. Moul. (2008) Point: Radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. Brachytherapy 7:4, 277-279
CrossRef242
Stacy Loeb, Kimberly A. Roehl, Brian T. Helfand, William J. Catalona. (2008) Complications of Open Radical Retropubic Prostatectomy in Potential Candidates for Active Monitoring. Urology 72:4, 887-891
CrossRef243
Daniel A. Barocas, Janet E. Cowan, Joseph A. Smith, Peter R. Carroll. (2008) What Percentage of Patients With Newly Diagnosed Carcinoma of the Prostate are Candidates for Surveillance? An Analysis of the CaPSURE™ Database. The Journal of Urology 180:4, 1330-1335
CrossRef244
N W Clarke. (2008) Survival from prostate cancer in England and Wales up to 2001. British Journal of Cancer 99, S78-S79
CrossRef245
J. Rüschoff, P. Middel, P. Albers. (2008) Active Surveillance des lokalisierten Prostatakarzinoms. Der Pathologe 29:5, 339-347
CrossRef246
Laurence Klotz. (2008) What is the best approach for screen-detected low volume cancers?—The case for observation. Urologic Oncology: Seminars and Original Investigations 26:5, 495-499
CrossRef247
M. Sieverding, U. Matterne, L. Ciccarello, H.-J. Luboldt. (2008) Prostatakarzinomfrüherkennung in Deutschland. Der Urologe 47:9, 1233-1238
CrossRef248
Konstantinos Hatzimouratidis, Kyriakos Moysidis, Athanasios Bekos, Alexandros Giakoumelos, Dimitrios Hatzichristou. (2008) What Is Adequate Management to Preserve Erectile Function after Unilateral Nerve-Sparing Radical Prostatectomy?. Journal of Endourology 22:9, 2029-2032
CrossRef249
David J. Kaplan, Paul L. Crispen, Richard E. Greenberg, David Y.T. Chen, Rosalia Viterbo, Mark K. Buyyounouski, Eric M. Horwitz, Robert G. Uzzo. (2008) Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens. Urology 72:3, 654-658
CrossRef250
Fayez T. Hammad. (2008) Radical Prostatectomy. Annals of the New York Academy of Sciences 1138:1, 267-277
CrossRef251
S Namiki, L Kwan, M Kagawa-Singer, T Tochigi, N Ioritani, A Terai, Y Arai, M S Litwin. (2008) Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. Prostate Cancer and Prostatic Diseases 11:3, 298-302
CrossRef252
James E. Montie. (2008) Screen detected, low volume prostate cancer: The case for active treatment. Urologic Oncology: Seminars and Original Investigations 26:5, 511-515
CrossRef253
A. Bill-Axelson, L. Holmberg, F. Filen, M. Ruutu, H. Garmo, C. Busch, S. Nordling, M. Haggman, S.-O. Andersson, S. Bratell, A. Spangberg, J. Palmgren, H.-O. Adami, J.-E. Johansson, . (2008) Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. JNCI Journal of the National Cancer Institute 100:16, 1144-1154
CrossRef254
T. J. Wilt. (2008) SPCG-4: A Needed START to PIVOTal Data to Promote and ProtecT Evidence-Based Prostate Cancer Care. JNCI Journal of the National Cancer Institute 100:16, 1123-1125
CrossRef255
(2008) RESPONSE TO THE LETTER. The American Journal of Gastroenterology
CrossRef256
B. Arndt, M. Kwiatkowski, F. Recker. (2008) Stand der Prostatakarzinomvorsorge im Jahr 2008. Der Urologe 47:8, 969-974
CrossRef257
Amy M Lin, Eric J Small. (2008) Prostate cancer update: 2007. Current Opinion in Internal Medicine 7:4, 379-384
CrossRef258
Zohar A Dotan. (2008) Bone imaging in prostate cancer. Nature Clinical Practice Urology 5:8, 434-444
CrossRef259
J. Stephen Jones, John C. Rewcastle, Bryan J. Donnelly, Franco M. Lugnani, Louis L. Pisters, Aaron E. Katz. (2008) Whole Gland Primary Prostate Cryoablation: Initial Results From the Cryo On-Line Data Registry. The Journal of Urology 180:2, 554-558
CrossRef260
E. David Crawford, Per-Anders Abrahamsson. (2008) PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests?. European Urology 54:2, 262-273
CrossRef261
Andrea Gallina, Nazareno Suardi, Francesco Montorsi, Umberto Capitanio, Claudio Jeldres, Fred Saad, Markus Graefen, Shahrokh F. Shariat, Hugues Widmer, Philippe Arjane, François Péloquin, Paul Perrotte, Pierre I. Karakiewicz. (2008) Mortality at 120 days after prostatic biopsy: A population-based study of 22,175 men. International Journal of Cancer 123:3, 647-652
CrossRef262
S A Narod, S Neuhausen, G Vichodez, S Armel, H T Lynch, P Ghadirian, S Cummings, O Olopade, D Stoppa-Lyonnet, F Couch, T Wagner, E Warner, W D Foulkes, H Saal, J Weitzel, A Tulman, A Poll, R Nam, P Sun. (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer 99:2, 371-374
CrossRef263
Tiffany Daly, Brigid E Hickey, Margot Lehman, Daniel P Francis, Tiffany Daly. 2008. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. .
CrossRef264
Simon Evans, Chris Metcalfe, Fowzia Ibrahim, Raj Persad, Yoav Ben-Shlomo. (2008) Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. International Journal of Cancer 123:2, 430-435
CrossRef265
N.M. deSouza, S.F. Riches, N.J. VanAs, V.A. Morgan, S.A. Ashley, C. Fisher, G.S. Payne, C. Parker. (2008) Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clinical Radiology 63:7, 774-782
CrossRef266
Koji Kawamura, Hiroyoshi Suzuki, Naoto Kamiya, Takashi Imamoto, Masashi Yano, Junichiro Miura, Masaki Shimbo, Noriyuki Suzuki, Hiroomi Nakatsu, Tomohiko Ichikawa. (2008) Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. International Journal of Urology 15:7, 598-603
CrossRef267
Deborah A. Kuban. (2008) In Reply to Drs. Schulz and Kagan. International Journal of Radiation Oncology*Biology*Physics 71:4, 1288
CrossRef268
Stacy Loeb, Kimberly A. Roehl, C. Shad Thaxton, William J. Catalona. (2008) Combined Prostate-specific Antigen Density and Biopsy Features to Predict “Clinically Insignificant” Prostate Cancer. Urology 72:1, 143-147
CrossRef269
Michael J. Barry. (2008) Editorial Comment on: Poor Overall Survival in Septa- and Octogenarian Patients after Radical Prostatectomy and Radiotherapy for Prostate Cancer: A Population-Based Study of 6183 Men. European Urology 54:1, 116-117
CrossRef270
Masataka Nakano, Hiroyuki Takahashi, Taizo Shiraishi, Tomoe Lu, Masakuni Furusato, Shin Wakui, Hiroshi Hano. (2008) Prediction of clinically insignificant prostate cancer by detection of allelic imbalance at 6q, 8p and 13q. Pathology International 58:7, 415-420
CrossRef271
Laurence Klotz. (2008) Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nature Clinical Practice Urology 5:7, 362-363
CrossRef272
Jan Adolfsson. (2008) Watchful waiting and active surveillance: the current position. BJU International 102:1, 10-14
CrossRef273
Fei Dong, Michael W. Kattan, Ewout W. Steyerberg, J. Stephen Jones, Andrew J. Stephenson, Fritz H. Schröder, Eric A. Klein. (2008) Validation of Pretreatment Nomograms for Predicting Indolent Prostate Cancer: Efficacy in Contemporary Urological Practice. The Journal of Urology 180:1, 150-154
CrossRef274
Peter Albertsen. (2008) Should patients consider active surveillance?. Cancer 112:12, 2631-2634
CrossRef275
Alon Z. Weizer, Maha H. Hussain. 2008. Prostate Cancer Prevention Trial. .
CrossRef276
Peter C. Albertsen. (2008) The face of high risk prostate cancer. World Journal of Urology 26:3, 205-210
CrossRef277
Liqian Liu, Ann L. Coker, Xianglin L. Du, Janice N. Cormier, Charles E. Ford, Shenying Fang. (2008) Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer. Journal of Surgical Oncology 97:7, 583-591
CrossRef278
L. Weißbach, J. Altwein, T. Wiegel. (2008) Strategien zur Behandlung des lokal begrenzten Prostatakarzinoms. best practice onkologie 3:3, 22-30
CrossRef279
Fritz H. Schröder. (2008) Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms. European Urology 53:6, 1129-1137
CrossRef280
Stacy Loeb, David J. Hernandez, Leslie A. Mangold, Elizabeth B. Humphreys, Marilyn Agro, Patrick C. Walsh, Alan W. Partin, Misop Han. (2008) Progression after radical prostatectomy for men in their thirties compared to older men. BJU International 101:12, 1503-1506
CrossRef281
Ole Johan Halvorsen. (2008) Molecular and prognostic markers in prostate cancer. APMIS 116, 1-62
CrossRef282
Shunichi Namiki, Lorna Kwan, Marjorie Kagawa-Singer, Akito Terai, Yoichi Arai, Mark S. Litwin. (2008) Urinary Quality of Life After Prostatectomy or Radiation for Localized Prostate Cancer: A Prospective Longitudinal Cross-Cultural Study Between Japanese and U.S. Men. Urology 71:6, 1103-1108
CrossRef283
Scott M. Gilbert. (2008) Separating surgical quality from causality—Gaining perspective in the debate on lymph node count and extent of lymphadenectomy. Cancer 112:11, 2331-2333
CrossRef284
Michele Lodde, François Harel, Louis Lacombe, Yves Fradet. (2008) Substratification of high-risk localised prostate cancer treated by radical prostatectomy. World Journal of Urology 26:3, 225-229
CrossRef285
L. Michael Glode. (2008) Metabolic syndrome and prostate cancer. Cancer 112:10, 2103-2105
CrossRef286
Anthony Zietman. (2008) ACTIVE SURVEILLANCE: A SAFE, LOW-COST PROGNOSTIC TEST FOR PROSTATE CANCER. BJU International 101:9, 1059-1060
CrossRef287
Michael Froehner, Rainer Koch, Rainer J. Litz, Oliver W. Hakenberg, Sven Oehlschlaeger, Manfred P. Wirth. (2008) Interaction Between Age and Comorbidity as Predictors of Mortality After Radical Prostatectomy. The Journal of Urology 179:5, 1823-1829
CrossRef288
Marc A. Dall’Era, Christopher J. Kane. (2008) Watchful waiting versus active surveillance: Appropriate patient selection. Current Urology Reports 9:3, 211-216
CrossRef289
Mark A Rubin. (2008) Targeted therapy of cancer: new roles for pathologists—prostate cancer. Modern Pathology 21, S44-S55
CrossRef290
Badrinath R. Konety, Janet E. Cowan, Peter R. Carroll. (2008) Patterns of Primary and Secondary Therapy for Prostate Cancer in Elderly Men: Analysis of Data From CaPSURE®. The Journal of Urology 179:5, 1797-1803
CrossRef291
Simon M Collin, Richard M Martin, Chris Metcalfe, David Gunnell, Peter C Albertsen, David Neal, Freddie Hamdy, Peter Stephens, J Athene Lane, Rollo Moore, Jenny Donovan. (2008) Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. The Lancet Oncology 9:5, 445-452
CrossRef292
Jan-Erik Damber, Gunnar Aus. (2008) Prostate cancer. The Lancet 371:9625, 1710-1721
CrossRef293
Fernando J. Bianco. (2008) Radical prostatectomy: Surgical planning, execution, and outcomes. Current Urology Reports 9:3, 231-236
CrossRef294
Jared Cox, Christopher L Amling. (2008) Current decision-making in prostate cancer therapy. Current Opinion in Urology 18:3, 275-278
CrossRef295
Ased S. M. Ali, Freddie C. Hamdy. (2008) The spectrum of prostate cancer care: From curative intent to palliation. Current Prostate Reports 6:2, 56-63
CrossRef296
Peter C Albertsen. (2008) Should men over the age of 65 years receive PSA screening? Argument against. Nature Clinical Practice Urology 5:5, 232-233
CrossRef297
Simonetta Fracalanza, Vincenzo Ficarra, Stefano Cavalleri, Antonio Galfano, Giacomo Novara, Angelo Mangano, Mario Plebani, Walter Artibani. (2008) Is robotically assisted laparoscopic radical prostatectomy less invasive than retropubic radical prostatectomy? Results from a prospective, unrandomized, comparative study. BJU International 101:9, 1145-1149
CrossRef298
Scott M Gilbert. (2008) Shifting focus to cancer survivorship in prostate cancer: challenges and opportunities. Current Opinion in Urology 18:3, 326-332
CrossRef299
Amy M Lin, Eric J Small. (2008) Prostate cancer update: 2007. Current Opinion in Oncology 20:3, 294-299
CrossRef300
Jared M Whitson, Badrinath R Konety. (2008) Should men over the age of 65 years receive PSA screening? Argument in favor. Nature Clinical Practice Urology 5:5, 230-231
CrossRef301
Hans Lilja, David Ulmert, Andrew J. Vickers. (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews Cancer 8:4, 268-278
CrossRef302
Georg Bartsch, Wolfgang Horninger, Helmut Klocker, Alexandre Pelzer, Jasmin Bektic, Wilhelm Oberaigner, Harald Schennach, Georg Schäfer, Ferdinand Frauscher, Mathieu Boniol, Gianluca Severi, Chris Robertson, Peter Boyle, . (2008) Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU International 101:7, 809-816
CrossRef303
Pierre I. Karakiewicz, Nazareno Suardi, Shahrokh F. Shariat. (2008) The Search for Better Prognostic Factors for Men Treated for Localized Prostate Cancer Continues. European Urology 53:4, 689-690
CrossRef304
Robert Abouassaly, Brian R. Lane, J. Stephen Jones. (2008) Staging Saturation Biopsy in Patients with Prostate Cancer on Active Surveillance Protocol. Urology 71:4, 573-577
CrossRef305
Wayne S. Kendal. (2008) Dying with cancer. Cancer 112:6, 1354-1362
CrossRef306
Claartje Gosselaar, Monique J. Roobol, Stijn Roemeling, Tineke Wolters, Geert J.L.H. van Leenders, Fritz H. Schröder. (2008) The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU International 101:6, 685-690
CrossRef307
Peter Iversen, Martin Andreas Roder. (2008) The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy 8:3, 361-369
CrossRef308
Sabina Hussain, David Gunnell, Jenny Donovan, Sean McPhail, Freddie Hamdy, David Neal, Peter Albertsen, Julia Verne, Peter Stephens, Caroline Trotter, Richard M. Martin. (2008) Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975–2004. BJU International 101:5, 547-555
CrossRef309
Prokar Dasgupta, Krishna Patil, Chris Anderson, Roger Kirby. (2008) TRANSITION FROM OPEN TO ROBOTIC-ASSISTED RADICAL PROSTATECTOMY. BJU International 101:6, 667-668
CrossRef310
Stephen W. Marcella, George G. Rhoads, Jeffrey L. Carson, Frances Merlino, Homer Wilcox. (2008) Prostate-Specific Antigen Screening and Mortality from Prostate Cancer. Journal of General Internal Medicine 23:3, 248-253
CrossRef311
M. Graefen, S. Ahyai, R. Heuer, G. Salomon, T. Schlomm, H. Isbarn, L. Budäus, H. Heinzer, H. Huland. (2008) Aktive Überwachung des Prostatakarzinoms. Der Urologe 47:3, 261-269
CrossRef312
Ruth Etzioni, Alex Tsodikov, Angela Mariotto, Aniko Szabo, Seth Falcon, Jake Wegelin, Dante diTommaso, Kent Karnofski, Roman Gulati, David F. Penson, Eric Feuer. (2008) Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes & Control 19:2, 175-181
CrossRef313
Jason Hafron, Jihad H Kaouk. (2008) Technical advances in urological laparoscopic surgery. Expert Review of Medical Devices 5:2, 145-151
CrossRef314
W. Robert Lee. (2008) Technology Assessment: Vigilance Required. International Journal of Radiation Oncology*Biology*Physics 70:3, 652-653
CrossRef315
Eric A Singer, Dragan J Golijanin, Hiroshi Miyamoto, Edward M Messing. (2008) Androgen deprivation therapy for prostate cancer. Expert Opinion on Pharmacotherapy 9:2, 211-228
CrossRef316
Sari Laitinen, Paula M. Martikainen, Teemu Tolonen, Jorma Isola, Teuvo L.J. Tammela, Tapio Visakorpi. (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. International Journal of Cancer 122:3, 595-602
CrossRef317
Lionel S. Lim, Kevin Sherin. (2008) Screening for Prostate Cancer in U.S. Men. American Journal of Preventive Medicine 34:2, 164-170
CrossRef318
M. Fröhner, M. Wirth. (2008) Früherkennung des Prostatakarzinoms. Der Onkologe 14:2, 142-146
CrossRef319
Arputharaj J. Chelladurai, Thiru Gunendran, Caroline Nicholson, Shyam S. Matanhelia, Rosemary A. Blades. (2008) The economic and workload impact of ‘backdoor’ prostate-specific antigen screening on the UK National Health Service: a single-centre experience. BJU International 101:3, 289-292
CrossRef320
James A. Eastham, Michael W. Kattan, Paul Fearn, Gabrielle Fisher, Daniel M. Berney, Tim Oliver, Christopher S. Foster, Henrik Møller, Victor Reuter, Jack Cuzick, Peter Scardino. (2008) Local Progression among Men with Conservatively Treated Localized Prostate Cancer: Results from the Transatlantic Prostate Group. European Urology 53:2, 347-354
CrossRef321
G Attard, J Clark, L Ambroisine, G Fisher, G Kovacs, P Flohr, D Berney, C S Foster, A Fletcher, W L Gerald, H Moller, V Reuter, J S De Bono, P Scardino, J Cuzick, C S Cooper. (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27:3, 253-263
CrossRef322
Richard J. Bryant, Freddie C. Hamdy. (2008) Screening for Prostate Cancer: An Update. European Urology 53:1, 37-44
CrossRef323
Laurence Klotz. (2008) Active Surveillance for Favorable Risk Prostate Cancer: What Are the Results, and How Safe Is It?. Seminars in Radiation Oncology 18:1, 2-6
CrossRef324
André N. Vis, Stijn Roemeling, Ardine M.J. Reedijk, Suzie J. Otto, Fritz H. Schröder. (2008) Overall Survival in the Intervention Arm of a Randomized Controlled Screening Trial for Prostate Cancer Compared with a Clinically Diagnosed Cohort. European Urology 53:1, 91-98
CrossRef325
Anders Kjellman, Olof Akre, Ulf Norming, Magnus Törnblom, Ove Gustafsson. (2008) Dihydrotestosterone Levels and Survival in Screening-Detected Prostate Cancer: A 15-yr Follow-up Study. European Urology 53:1, 106-111
CrossRef326
Savita V. Dandapani, Martin G. Sanda. (2008) Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer. Seminars in Radiation Oncology 18:1, 67-72
CrossRef327
Peter Albertsen. (2008) Should men with low-risk, localized prostate cancer choose active surveillance or undergo a robotic prostatectomy?. Current Urology Reports 9:1, 1-2
CrossRef328
D Doddamani, A Kayastha. (2008) Prostate Cancer - What's New?. Medical Journal Armed Forces India 64:1, 51-56
CrossRef329
Sadao Kamidono, Shinichi Ohshima, Yoshihiko Hirao, Kazuhiro Suzuki, Yoichi Arai, Hiroyuki Fujimoto, Shin Egawa, Hideyuki Akaza, Isao Hara, Shiro Hinotsu, Yoshiyuki Kakehi, Tomonori Hasegawa. (2008) Evidence-based Clinical Practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition). International Journal of Urology 15:1, 1-18
CrossRef330
Vladimir Mouraviev, Thomas J Polascik. (2008) Avoiding surgery in prostate cancer patients with low-risk disease. Therapy 5:1, 25-36
CrossRef331
Axel Heidenreich, Gunnar Aus, Michel Bolla, Steven Joniau, Vsevolod B. Matveev, Hans Peter Schmid, Filliberto Zattoni. (2008) EAU Guidelines on Prostate Cancer. European Urology 53:1, 68-80
CrossRef332
Shomik Sengupta, Michael L. Blute, Stephanie M. Bagniewski, Brant Inman, Bradley C. Leibovich, Jeffrey M. Slezak, Robert P. Myers, Horst Zincke. (2008) After radical retropubic prostatectomy ‘insignificant’ prostate cancer has a risk of progression similar to low-risk ‘significant’ cancer. BJU International 101:2, 170-174
CrossRef333
Laurence Klotz. (2008) Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nature Clinical Practice Urology 5:1, 2-3
CrossRef334
Thomas E. Ahlering, James F. Borin, Douglas W. Skarecky. 2008. Oncologic Outcomes of Robotic Radical Prostatectomy. , 101-106.
CrossRef335
Walsh, Patrick C., DeWeese, Theodore L., Eisenberger, Mario A., . (2007) Localized Prostate Cancer. New England Journal of Medicine 357:26, 2696-2705
Full Text336
R. Kvale, A. Auvinen, H.-O. Adami, A. Klint, E. Hernes, B. Moller, E. Pukkala, H. H. Storm, L. Tryggvadottir, S. Tretli, R. Wahlqvist, E. Weiderpass, F. Bray. (2007) Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries. JNCI Journal of the National Cancer Institute 99:24, 1881-1887
CrossRef337
R K Nam, L Sugar, W Yang, S Srivastava, L H Klotz, L-Y Yang, A Stanimirovic, E Encioiu, M Neill, D A Loblaw, J Trachtenberg, S A Narod, A Seth. (2007) Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. British Journal of Cancer 97:12, 1690-1695
CrossRef338
L Holmes, W Chan, Z Jiang, X L Du. (2007) Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. Prostate Cancer and Prostatic Diseases 10:4, 388-395
CrossRef339
Laurence Klotz. (2007) Active surveillance for favorable-risk prostate cancer: who, how and why?. Nature Clinical Practice Oncology 4:12, 692-698
CrossRef340
Hiroyuki Nakanishi, Xuemei Wang, Atsushi Ochiai, Kiril Trpkov, Asli Yilmaz, J. Bryan Donnelly, John W. Davis, Patricia Troncoso, R. Joseph Babaian. (2007) A nomogram for predicting low-volume/low-grade prostate cancer. Cancer 110:11, 2441-2447
CrossRef341
P. Pierini, E. Baldassarre, B. Lillaz. (2007) Robotic prostatectomy: an opportunity. International Journal of Clinical Practice 61:12, 2133-2134
CrossRef342
Andrea Gallina, Alberto Briganti, Felix K.-H. Chun, Jochen Walz, Georg C. Hutterer, Andreas Erbersdobler, Christian Eichelberg, Thorsten Schlomm, Sascha A. Ahyai, Paul Perrotte, Fred Saad, Francesco Montorsi, Hartwig Huland, Markus Graefen, Pierre I. Karakiewicz. (2007) Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. BJU International 100:6, 1249-1253
CrossRef343
Yoichi Arai. (2007) Recent advances in nonsurgical management of localized prostate cancer. International Journal of Clinical Oncology 12:6, 393-394
CrossRef344
François Giuliano, Edouard Amar, Daniel Chevallier, Olivier Montaigne, Jean-Michel Joubert, Emmanuel Chartier-Kastler. (2007) How Urologists Manage Erectile Dysfunction after Radical Prostatectomy: A National Survey (REPAIR) by the French Urological Association. The Journal of Sexual Medicine 0:0, 071203213757004-???
CrossRef345
Andreas E. Nilsson, Stefan Carlsson, N. Martin Jonsson, Eric Onelöv, Gunnar Steineck, N. Peter Wiklund. (2007) Erectile function after robotic nerve sparing and semi-sparing of the neurovascular bundles. Journal of Robotic Surgery 1:3, 191-195
CrossRef346
Raj K. Goel, Jihad H. Kaouk. (2007) Optical coherence tomography: the past, present and future. Journal of Robotic Surgery 1:3, 179-184
CrossRef347
Benjamin D. Sommers, Clair J. Beard, Anthony V. D'Amico, Douglas Dahl, Irving Kaplan, Jerome P. Richie, Richard J. Zeckhauser. (2007) Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 110:10, 2210-2217
CrossRef348
Stijn Roemeling, Monique J. Roobol, Michael W. Kattan, Theo H. van der Kwast, Ewout W. Steyerberg, Fritz H. Schröder. (2007) Nomogram use for the prediction of indolent prostate cancer. Cancer 110:10, 2218-2221
CrossRef349
Arne Berg, Wolfgang Lilleby, Øyvind Sverre Bruland, Sophie Dorothea Fosså. (2007) 10-Year Survival and Quality of Life in Patients With High-Risk PN0 Prostate Cancer Following Definitive Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 69:4, 1074-1083
CrossRef350
Eric J. Bergstralh, Rosebud O. Roberts, Sara A. Farmer, Jeffrey M. Slezak, Michael M. Lieber, Steven J. Jacobsen. (2007) Population-Based Case-Control Study of PSA and DRE Screening on Prostate Cancer Mortality. Urology 70:5, 936-941
CrossRef351
Rinaa S. Punglia, Jennifer Cullen, David G. McLeod, Yongmei Chen, Anthony V. D'Amico. (2007) Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Cancer 110:9, 1973-1978
CrossRef352
Neil Fleshner, Alexandre R. Zlotta. (2007) Prostate cancer prevention. Cancer 110:9, 1889-1899
CrossRef353
Thomas L. Jang, Ofer Yossepowitch, Fernando J. Bianco, Peter T. Scardino. (2007) Low risk prostate cancer in men under age 65: The case for definitive treatment. Urologic Oncology: Seminars and Original Investigations 25:6, 510-514
CrossRef354
Josephine Hegarty, Ella Walsh. (2007) Prostate cancer treatment options (observation versus prostatectomy) – the available evidence. International Journal of Urological Nursing 1:3, 99-111
CrossRef355
Kevin C. Zorn, Andrea Gallina, Georg C. Hutterer, Jochen Walz, Arieh L. Shalhav, Gregory P. Zagaja, Luc Valiquette, Ofer N. Gofrit, Marcelo A. Orvieto, Jerome B. Taxy, Pierre I. Karakiewicz. (2007) External Validation of a Nomogram for Prediction of Side-Specific Extracapsular Extension at Robotic Radical Prostatectomy. Journal of Endourology 21:11, 1345-1352
CrossRef356
Laurence Klotz. (2007) Active surveillance for favorable risk prostate cancer: Rationale, risks, and results. Urologic Oncology: Seminars and Original Investigations 25:6, 505-509
CrossRef357
Peter Lembessis, Pavlos Msaouel, Antonis Halapas, Antigone Sourla, Zacharoula Panteleakou, Nikolaos Pissimissis, Constantine Milathianakis, John Bogdanos, Andreas Papaioannou, Evangelos Maragoudakis, Constantine Dardoufas, Theodoros Dimopoulos, Michael Koutsilieris. (2007) Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clinical Chemistry and Laboratory Medicine 45:11, 1488-1494
CrossRef358
Hashim Uddin Ahmed, Doug Pendse, Rowland Illing, Clare Allen, Jan HP van der Meulen, Mark Emberton. (2007) Will focal therapy become a standard of care for men with localized prostate cancer?. Nature Clinical Practice Oncology 4:11, 632-642
CrossRef359
H. K. Tsai, A. V. D'Amico, N. Sadetsky, M.-H. Chen, P. R. Carroll. (2007) Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality. JNCI Journal of the National Cancer Institute 99:20, 1516-1524
CrossRef360
Jan Adolfsson, Bernhard Tribukait, Seymour Levitt. (2007) The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic Value of Tumour Ploidy and Comorbidity. European Urology 52:4, 1028-1035
CrossRef361
Peter Albertsen. (2007) What Do We Really Know about Prostate Cancer?. European Urology 52:4, 948-950
CrossRef362
Phillip M. Pierorazio, Benjamin A. Spencer, Tara R. McCann, James M. McKiernan, Mitchell C. Benson. (2007) Preoperative Risk Stratification Predicts Likelihood of Concurrent PSA-Free Survival, Continence, and Potency (the Trifecta Analysis) After Radical Retropubic Prostatectomy. Urology 70:4, 717-722
CrossRef363
Kazuto Ito, Takumi Yamamoto, Mai Miyakubo, Hiroyuki Takechi, Masaru Ohi, Yasuhiro Shibata, Kazuhiro Suzuki. (2007) Lead Time of Prostate Cancer Detected in Population Based Screening for Prostate Cancer in Japan. The Journal of Urology 178:4, 1258-1264
CrossRef364
Jonathan D Tward, Dennis C Shrieve. (2007) Brachytherapy monotherapy for older men with prostate cancer. Aging Health 3:5, 653-661
CrossRef365
Russel S. Taichman, Robert D. Loberg, Rohit Mehra, Kenneth J. Pienta. (2007) The evolving biology and treatment of prostate cancer. Journal of Clinical Investigation 117:9, 2351-2361
CrossRef366
Andrew Judge, Simon Evans, David J. Gunnell, Peter C. Albertsen, Julia Verne, Richard M. Martin. (2007) Patient outcomes and length of hospital stay after radical prostatectomy for prostate cancer: analysis of Hospital Episodes Statistics for England. BJU International 0:0, 070907033641007-???
CrossRef367
Laurence Klotz. (2007) Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?. Current Urology Reports 8:5, 341-344
CrossRef368
Julia H. Hayes, Michael J. Barry, Philip W. Kantoff, James E. Stahl. (2007) PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER: A DECISION-ANALYTICAL PERSPECTIVE. BJU International 100:3, 486-488
CrossRef369
Andrew W. Roddam, Freddie C. Hamdy, Naomi E. Allen, Christopher P. Price, . (2007) The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. BJU International 100:3, 514-517
CrossRef370
David F. Penson. (2007) Quality of Life After Therapy for Localized Prostate Cancer. The Cancer Journal 13:5, 318-326
CrossRef371
Al B. Barqawi, E David Crawford. (2007) The Current Use and Future Trends of Focal Surgical Therapy in the Management of Localized Prostate Cancer. The Cancer Journal 13:5, 313-317
CrossRef372
Mark Scholz, Richard Lam, Stephen Strum, Robert Jennrich, Henry Johnson, Tom Trilling. (2007) Prostate Cancer-Specific Survival and Clinical Progression-Free Survival in Men with Prostate Cancer Treated Intermittently with Testosterone Inactivating Pharmaceuticals. Urology 70:3, 506-510
CrossRef373
Tom Pickles, J. Dean Ruether, Lorna Weir, Linda Carlson, Fabijana Jakulj, . (2007) Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU International 100:3, 544-551
CrossRef374
Nima Sharifi, Barnett S. Kramer. (2007) Screening for Prostate Cancer: Current Status and Future Prospects. The American Journal of Medicine 120:9, 743-745
CrossRef375
Matthew R. Cooperberg, Jeannette M. Broering, Philip W. Kantoff, Peter R. Carroll. (2007) Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment. The Journal of Urology 178:3, S14-S19
CrossRef376
Nicholas J. van As, Chris C. Parker. (2007) Active Surveillance With Selective Radical Treatment for Localized Prostate Cancer. The Cancer Journal 13:5, 289-294
CrossRef377
David F. Penson. (2007) Survival associated with treatment vs. observation of localized prostate cancer in elderly men. Urologic Oncology: Seminars and Original Investigations 25:5, 440-441
CrossRef378
C. Börgermann, G. Matnjani, T. Wiegel, S. Krege. (2007) Prostatakarzinom. Der Onkologe 13:9, 840-846
CrossRef379
Philip W. Kantoff, Tomasz M. Beer, Anthony V. D’Amico, Robert S. DiPaola, Mario A. Eisenberger, Maha H.A. Hussain, William Kevin Kelly, Paul Mathew, Michael J. Morris, Charles J. Ryan, Howard M. Sandler, Ian M. Thompson, Peter R. Carroll. (2007) Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference. The Journal of Urology 178:3, S5-S8
CrossRef380
Laura M. Kenny, Sarah Ngan, Jonathan Waxman. (2007) ?TIME, GENTLEMEN, PLEASE? FOR WATCHFUL WAITING IN PROSTATE CANCER?. BJU International 100:2, 244-246
CrossRef381
Monish Aron, Jihad H. Kaouk, Nicholas J. Hegarty, Jose Roberto Colombo, Jr., Georges-Pascal Haber, Benjamin I. Chung, Ming Zhou, Inderbir S. Gill. (2007) Second Prize: Preliminary Experience with the Niris ™ Optical Coherence Tomography System during Laparoscopic and Robotic Prostatectomy. Journal of Endourology 21:8, 814-818
CrossRef382
Christopher R. Porter, Andrea Gallina, Koichi Kodama, Robert P. Gibbons, Roy Correa, Paul Perrotte, Pierre I. Karakiewicz. (2007) Prostate Cancer-Specific Survival in Men Treated with Hormonal Therapy after Failure of Radical Prostatectomy. European Urology 52:2, 446-454
CrossRef383
Jamie A. Cesaretti, Johnny Kao, Nelson N. Stone, Richard G. Stock. (2007) Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at ? 7
years of follow-up. BJU International 100:2, 362-367
CrossRef384
Josephine Hegarty, Paul V Beirne, Harry Comber, Meredith Wallace, Meredith Wallace. 2007. Watchful waiting versus prostatectomy for prostate cancer. .
CrossRef385
F Demichelis, K Fall, S Perner, O Andrén, F Schmidt, S R Setlur, Y Hoshida, J-M Mosquera, Y Pawitan, C Lee, H-O Adami, L A Mucci, P W Kantoff, S-O Andersson, A M Chinnaiyan, J-E Johansson, M A Rubin. (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:31, 4596-4599
CrossRef386
Richard M. Hoffman, Thomas Denberg, William C. Hunt, Ann S. Hamilton. (2007) Prostate Cancer Testing following a Negative Prostate Biopsy: Over Testing the Elderly. Journal of General Internal Medicine 22:8, 1139-1143
CrossRef387
Alexandre E. Pelzer, Jasmin Bektic, Thomas Akkad, Stefano Ongarello, Georg Schaefer, Christian Schwentner, Ferdinand Frauscher, Georg Bartsch, Wolfgang Horninger. (2007) Under Diagnosis and Over Diagnosis of Prostate Cancer in a Screening Population With Serum PSA 2 to 10 ng/ml. The Journal of Urology 178:1, 93-97
CrossRef388
Bahaa S. Malaeb, Hani H. Rashid, Yair Lotan, Seyyed M. Khoddami, Shahrokh F. Shariat, Arthur I. Sagalowsky, John D. McConnell, Claus G. Roehrborn, Kenneth S. Koeneman. (2007) Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. Urologic Oncology: Seminars and Original Investigations 25:4, 291-297
CrossRef389
Guglielmo Breda, Antonio Celia. (2007) How to preserve potency and continence in localized prostate cancer. BJU International 100:s2 Prostate Can, 29-31
CrossRef390
Bob Djavan, Vincent Ravery, Bernardo Rocco, Alexandre Zlotta, Maurizio Brausi, Markus Margreiter, Peter Hammerer, Amir Kaisary, Theodore Anagnostou, Imre Romics, Pitor Dobronski, Ottavio De Cobelli, Michael Marberger. (2007) European Study of Radical Prostatectomy: time trends in Europe, 1993?2005. BJU International 100:s2 Prostate Can, 22-25
CrossRef391
Anne Katz. (2007) Quality of Life for Men With Prostate Cancer. Cancer Nursing 30:4, 302-308
CrossRef392
Michael Marberger. (2007) Current prostate cancer: 20
CrossRef393
Stacy Loeb, William J Catalona. (2007) Early versus delayed intervention for prostate cancer: the case for early intervention. Nature Clinical Practice Urology 4:7, 348-349
CrossRef394
Per-Anders Abrahamsson. (2007) Active surveillance vs radical prostatectomy. BJU International 100:s2 Prostate Can, 26-28
CrossRef395
David F. Penson, June M. Chan. (2007) Prostate Cancer. The Journal of Urology 177:6, 2020-2029
CrossRef396
Erica H. Lambert, Kimberly Bolte, Puneet Masson, Aaron E. Katz. (2007) Focal Cryosurgery: Encouraging Health Outcomes for Unifocal Prostate Cancer. Urology 69:6, 1117-1120
CrossRef397
Jan Adolfsson. (2007) Can we define which patients with prostate cancer are suitable for expectant management?. Nature Clinical Practice Urology 4:6, 308-309
CrossRef398
Rob Joffe, Laurence H. Klotz. (2007) Results of Unilateral Genitofemoral Nerve Grafts with Contralateral Nerve Sparing During Radical Prostatectomy. Urology 69:6, 1161-1164
CrossRef399
Judy M. Choi, Christian J. Nelson, Jason Stasi, John P. Mulhall. (2007) Orgasm Associated Incontinence (Climacturia) Following Radical Pelvic Surgery: Rates of Occurrence and Predictors. The Journal of Urology 177:6, 2223-2226
CrossRef400
Ronnie Ortiz, Jessie L-S. Au, Ze Lu, Yuebo Gan, M. Guillaume Wientjes. (2007) Biodegradable intraprostatic doxorubicin implants. The AAPS Journal 9:2, E241-E250
CrossRef401
Ian Thompson, James Brantley Thrasher, Gunnar Aus, Arthur L. Burnett, Edith D. Canby-Hagino, Michael S. Cookson, Anthony V. D’Amico, Roger R. Dmochowski, David T. Eton, Jeffrey D. Forman, S. Larry Goldenberg, Javier Hernandez, Celestia S. Higano, Stephen R. Kraus, Judd W. Moul, Catherine M. Tangen. (2007) Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. The Journal of Urology 177:6, 2106-2131
CrossRef402
Michael J. Barry. (2007) Re: Survival Associated with Treatment vs Observation of Localized Prostate Cancer in Elderly Men. European Urology 51:6, 1751
CrossRef403
Isao Hara, Gaku Kawabata, Kazushi Tanaka, Naoki Kanomata, Hideaki Miyake, Atsushi Takenaka, Masato Fujisawa. (2007) Oncological outcome of laparoscopic prostatectomy. International Journal of Urology 14:6, 515-520
CrossRef404
Eric A. Klein, Robert Abouassaly. (2007) Re: Survival of Men with Clinically Localized Prostate Cancer Treated with Prostatectomy, Brachytherapy, or No Definitive Treatment: Impact of Age at Diagnosis. European Urology 51:6, 1752
CrossRef405
Gregory L. Lacy, Douglas W. Soderdahl, Javier Hernandez. (2007) Optimal cost-effective staging evaluations in prostate cancer. Current Urology Reports 8:3, 190-196
CrossRef406
Thomas W. Flaig, Lih-Jen Su, Gail Harrison, Rajesh Agarwal, Leonard Michael Glodé. (2007) Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. International Journal of Cancer 120:9, 2028-2033
CrossRef407
Rohit Mehra, Scott A Tomlins, Ronglai Shen, Owais Nadeem, Lei Wang, John T Wei, Kenneth J Pienta, Debashis Ghosh, Mark A Rubin, Arul M Chinnaiyan, Rajal B Shah. (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology 20:5, 538-544
CrossRef408
Stijn Roemeling, Monique J. Roobol, Stijn H. de Vries, Tineke Wolters, Claartje Gosselaar, Geert J.L.H. van Leenders, Fritz H. Schröder. (2007) Active Surveillance for Prostate Cancers Detected in Three Subsequent Rounds of a Screening Trial: Characteristics, PSA Doubling Times, and Outcome. European Urology 51:5, 1244-1251
CrossRef409
Sven Perner, Matthias D. Hofer, Robert Kim, Rajal B. Shah, Haojie Li, Peter Möller, Richard E. Hautmann, Juergen E. Gschwend, Rainer Kuefer, Mark A. Rubin. (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology 38:5, 696-701
CrossRef410
Ased S. M. Ali, Freddie C. Hamdy. (2007) The spectrum of prostate cancer care: From curative intent to palliation. Current Urology Reports 8:3, 245-252
CrossRef411
Peter T Scardino. (2007) Intoxicated by technology: are we keeping our eyes on the prize?. Nature Clinical Practice Urology 4:5, 231-231
CrossRef412
K. Fall, H. Garmo, O. Andren, A. Bill-Axelson, J. Adolfsson, H.-O. Adami, J.-E. Johansson, L. Holmberg. (2007) Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer. JNCI Journal of the National Cancer Institute 99:7, 526-532
CrossRef413
Julie N. Graff, Motomi Mori, Hong Li, Mark Garzotto, David Penson, Arnold L. Potosky, Tomasz M. Beer. (2007) Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study. The Journal of Urology 177:4, 1307-1312
CrossRef414
André N. Vis, Stijn Roemeling, Ries Kranse, Fritz H. Schröder, Theo H. van der Kwast. (2007) Should We Replace the Gleason Score with the Amount of High-Grade Prostate Cancer?. European Urology 51:4, 931-939
CrossRef415
C. H. Bangma, S. Roemeling, F. H. Schröder. (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World Journal of Urology 25:1, 3-9
CrossRef416
Badereddin Al-Ali Mohamad, Martin Marszalek, Clemens Brössner, Anton Ponholzer, Clemens Wehrberger, Manfred Willinger, Stephan Madersbacher. (2007) Radical Prostatectomy in Austria: A Nationwide Analysis of 16,524 Cases. European Urology 51:3, 684-689
CrossRef417
Stacy Loeb, Kimberly A. Roehl, William J. Catalona, Robert B. Nadler. (2007) Prostate Specific Antigen Velocity Threshold for Predicting Prostate Cancer in Young Men. The Journal of Urology 177:3, 899-902
CrossRef418
Peter C. Albertsen, James A. Hanley, David F. Penson, George Barrows, Judith Fine. (2007) 13-Year Outcomes Following Treatment for Clinically Localized Prostate Cancer in a Population Based Cohort. The Journal of Urology 177:3, 932-936
CrossRef419
David Gillatt, Laurence Klotz, Colleen Lawton, Kurt Miller, Heather Payne. (2007) Localised and Locally Advanced Prostate Cancer: Who to Treat and How?. European Urology Supplements 6:3, 334-343
CrossRef420
Ashutosh Tewari, George Divine, Peter Chang, M. Mendel Shemtov, Matthew Milowsky, David Nanus, Mani Menon. (2007) Long-Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy—A Propensity Scoring Approach. The Journal of Urology 177:3, 911-915
CrossRef421
Bernardo Rocco, Bob Djavan. (2007) Robotic prostatectomy: facts or fiction?. The Lancet 369:9563, 723-724
CrossRef422
Yair Lotan. (2007) Re: Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. European Urology 51:2, 567-568
CrossRef423
Peter Albers. (2007) Do We Need the Final Results of the ERSPC Trial?. European Urology 51:2, 291-292
CrossRef424
Peter C Albertsen. (2007) Does radical prostatectomy provide a survival benefit as primary treatment for high-grade prostate cancer?. Nature Clinical Practice Urology 4:2, 68-69
CrossRef425
Felix K.-H. Chun, Alberto Briganti, Claudio Jeldres, Andrea Gallina, Andreas Erbersdobler, Thorsten Schlomm, Jochen Walz, Christian Eichelberg, Georg Salomon, Alexander Haese, Eike Currlin, Sascha A. Ahyai, François Bénard, Hartwig Huland, Markus Graefen, Pierre I. Karakiewicz. (2007) Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. European Journal of Cancer 43:3, 536-543
CrossRef426
Mark Pomerantz, Philip Kantoff. (2007) Advances in the Treatment of Prostate Cancer. Annual Review of Medicine 58:1, 205-220
CrossRef427
H.G. van der Poel. (2007) Molecular markers in the diagnosis of prostate cancer. Critical Reviews in Oncology/Hematology 61:2, 104-139
CrossRef428
D. Hodgson, P. Acher, D. Cahill. (2007) An update on localised prostate cancer. International Journal of Clinical Practice 61:2, 315-319
CrossRef429
Susan Halabi, Nicholas J. Vogelzang, San-San Ou, Eric J. Small. (2007) The Impact of Prior Radical Prostatectomy in Men With Metastatic Castration Recurrent Prostate Cancer: A Pooled Analysis of 9 Cancer and Leukemia Group B Trials. The Journal of Urology 177:2, 531-534
CrossRef430
Michel B. Choueiri, Shi-Ming Tu, Li-Yuan Yu-Lee, Sue-Hwa Lin. (2007) The central role of osteoblasts in the metastasis of prostate cancer. Cancer and Metastasis Reviews 25:4, 601-609
CrossRef431
A.S. Kibel. (2007) Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men. Yearbook of Urology 2007, 165-167
CrossRef432
Matthew R. Hotston, Helena Burden, Ramesh Thurairaja, Jonathan McFarlane, Rajendra A. Persad. (2007) YOUNG MEN WITH PROSTATE CANCER: ARE THEY DIFFERENT AND HOW SHOULD THEY BE MANAGED?. BJU International 99:1, 5-7
CrossRef433
Khatami Ali, Aus Gunnar, Damber Jan-Erik, Lilja Hans, Lodding Pär, Hugosson Jonas. (2007) PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. International Journal of Cancer 120:1, 170-174
CrossRef434
Stephen Marcella, Cristine D. Delnevo, Steven S. Coughlin. (2007) A National Survey of Medical Students’ Beliefs and Knowledge in Screening for Prostate Cancer. Journal of General Internal Medicine 22:1, 80-85
CrossRef435
David B.Y. Syme, Niall M. Corcoran, David M. Bouchier-Hayes, Wayne A. Morrison, Anthony J. Costello. (2007) The Effect of Androgen Status on the Structural and Functional Success of Cavernous Nerve Grafting in an Experimental Rat Model. The Journal of Urology 177:1, 390-394
CrossRef436
D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, J. T. Wei. (2006) RESPONSE: Re: Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. JNCI Journal of the National Cancer Institute 98:24, 1826-1826
CrossRef437
Ashutosh Tewari, Jay D. Raman, Peter Chang, Sandhya Rao, George Divine, Mani Menon. (2006) Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 68:6, 1268-1274
CrossRef438
Freddie C. Hamdy. (2006) Re: Incidence of Initial Local Therapy Among Men with Lower-Risk Prostate Cancer in the United States. European Urology 50:6, 1368-1370
CrossRef439
Christopher Sweeney. (2006) The Case for Systemic Therapy Alone for Prostate Cancer. The Journal of Urology 176:6, S42-S46
CrossRef440
P. Paula Hruska, Joel Picus. (2006) The role of primary chemotherapy for prostate cancer: Has the time come?. Current Prostate Reports 4:4, 157-162
CrossRef441
Matthew R. Cooperberg, Stephen J. Freedland, David J. Pasta, Eric P. Elkin, Joseph C. Presti, Christopher L. Amling, Martha K. Terris, William J. Aronson, Christopher J. Kane, Peter R. Carroll. (2006) Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 107:10, 2384-2391
CrossRef442
Jonathan D. Tward, Christopher M. Lee, Lisa M. Pappas, Aniko Szabo, David K. Gaffney, Dennis C. Shrieve. (2006) Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment. Cancer 107:10, 2392-2400
CrossRef443
Gerrit Draisma, Renske Postma, Fritz H. Schröder, Theo H. van der Kwast, Harry J. de Koning. (2006) Gleason score, age and screening: Modeling dedifferentiation in prostate cancer. International Journal of Cancer 119:10, 2366-2371
CrossRef444
J Cuzick, G Fisher, M W Kattan, D Berney, T Oliver, C S Foster, H Møller, V Reuter, P Fearn, J Eastham, P Scardino. (2006) Long-term outcome among men with conservatively treated localised prostate cancer. British Journal of Cancer 95:9, 1186-1194
CrossRef445
Deb Feldman-Stewart, Sarah Brennenstuhl, Michael D Brundage, Tom Roques. (2006) An explicit values clarification task: Development and validation. Patient Education and Counseling 63:3, 350-356
CrossRef446
Hideo Yasunaga, Hiroo Ide, Tomoaki Imamura, Kazuhiko Ohe. (2006) Benefit evaluation of mass screening for prostate cancer: Willingness-to-pay measurement using contingent valuation. Urology 68:5, 1046-1050
CrossRef447
Fernando P. Secin, Fernando J. Bianco, Nicholas T. Karanikolas, Karim Touijer, Bertrand Guillonneau. (2006) Oncologic Outcomes of Laparoscopic Radical Prostatectomy: Intermediate-Term Follow-up. European Urology Supplements 5:19, 934-941
CrossRef448
Timothy J. Bradford, Scott A. Tomlins, Xiaoju Wang, Arul M. Chinnaiyan. (2006) Molecular markers of prostate cancer. Urologic Oncology: Seminars and Original Investigations 24:6, 538-551
CrossRef449
R. Houston Thompson, Jeffrey M. Slezak, W. Scott Webster, Michael M. Lieber. (2006) Radical prostatectomy for octogenarians: How old is too old?. Urology 68:5, 1042-1045
CrossRef450
Shabbir M.H. Alibhai, Marc Leach, George Tomlinson, Murray D. Krahn, Neil Fleshner, Gary Naglie. (2006) Rethinking 30-day mortality risk after radical prostatectomy. Urology 68:5, 1057-1060
CrossRef451
Rowland Illing, Mark Emberton. (2006) Sonablate ® -500: transrectal high-intensity focused ultrasound for the treatment of prostate cancer. Expert Review of Medical Devices 3:6, 717-729
CrossRef452
Joshua H. Petit, Ming-Hui Chen, Marian Loffredo, Brenda Sussman, Andrew A. Renshaw, Anthony V. D'Amico. (2006) Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer 107:9, 2180-2185
CrossRef453
Kimberly A. Roehl, Scott E. Eggener, Stacy Loeb, Norm D. Smith, Jo Ann V. Antenor, William J. Catalona. (2006) Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results. Urologic Oncology: Seminars and Original Investigations 24:6, 465-471
CrossRef454
Gunnar Aus. (2006) Current Status of HIFU and Cryotherapy in Prostate Cancer – A Review. European Urology 50:5, 927-934
CrossRef455
C Metcalfe, J A Lane, F Hamdy, D Neal, J L Donovan. (2006) A model of the natural history of screen-detected prostate cancer. British Journal of Cancer 95:8, 1122-1123
CrossRef456
V. Egorov, S. Ayrapetyan, A.P. Sarvazyan. (2006) Prostate mechanical imaging: 3-D image composition and feature calculations. IEEE Transactions on Medical Imaging 25:10, 1329-1340
CrossRef457
William G. Nelson, Angelo M. De Marzo. 2006. The Molecular Pathogenesis and Pathophysiology of Prostate Cancer. , 1-25.
CrossRef458
Laurence Klotz. (2006) Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Current Treatment Options in Oncology 7:5, 355-362
CrossRef459
MILES A. GOLDSTRAW, PROCAR DASGUPTA, CHRISTOPHER ANDERSON, KRISHNA PATIL, ROGER KIRBY. (2006) DOES ROBOTICALLY ASSISTED RADICAL PROSTATECTOMY RESULT IN BETTER PRESERVATION OF ERECTILE FUNCTION?. BJU International 98:4, 721-722
CrossRef460
Stijn Roemeling, Monique J. Roobol, Renske Postma, Claartje Gosselaar, Theo H. van der Kwast, Chris H. Bangma, Fritz H. Schröder. (2006) Management and Survival of Screen-Detected Prostate Cancer Patients who Might Have Been Suitable for Active Surveillance. European Urology 50:3, 475-482
CrossRef461
HIDEYUKI AKAZA, YUKIO HOMMA, MICHIYUKI USAMI, YOSHIHIKO HIRAO, TOMOYASU TSUSHIMA, KIYOKI OKADA, MASAO YOKOYAMA, YASUO OHASHI, YOSHIO ASO, . (2006) Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU International 98:3, 573-579
CrossRef462
Michael Froehner, Rainer Koch, Rainer J. Litz, Oliver W. Hakenberg, Sven Oehlschlaeger, Manfred P. Wirth. (2006) Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age. Urology 68:3, 583-586
CrossRef463
C. Börgermann, M. Sieverding, P. Fornara, M. Graefen, P. Hammerer, A. Semjonow, F. Schröder, H. Rübben. (2006) PSA 2010 – Aufbruch in eine neue Ära der Früherkennung des Prostatakarzinom. Der Urologe 45:S04, 127-133
CrossRef464
D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, J. T. Wei. (2006) Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. JNCI Journal of the National Cancer Institute 98:16, 1134-1141
CrossRef465
Xue Q. Yu, Dianne L. O'Connell, Robert W. Gibberd, Alan S. Coates, Bruce K. Armstrong. (2006) Trends in survival and excess risk of death after diagnosis of cancerin 1980–1996 in New South Wales, Australia. International Journal of Cancer 119:4, 894-900
CrossRef466
Timothy J. Bradford, James E. Montie, Khaled S. Hafez. (2006) The Role of Imaging in the Surveillance of Urologic Malignancies. Urologic Clinics of North America 33:3, 377-396
CrossRef467
P. W. DICKMAN, H.-O. ADAMI. (2006) Interpreting trends in cancer patient survival. Journal of Internal Medicine 260:2, 103-117
CrossRef468
Fritz H. Schröder. (2006) For the motion. European Urology 50:2, 377-379
CrossRef469
Lars Holmberg, Anna Bill-Axelson, Hans Garmo, Juni Palmgren, Bo Johan Norlén, Hans Olov Adami, Jan Erik Johansson. (2006) Prognostic Markers Under Watchful Waiting and Radical Prostatectomy. Hematology/Oncology Clinics of North America 20:4, 845-855
CrossRef470
Robert L. Grubb, Itay Y. Vardi, Sam B. Bhayani, Adam S. Kibel. (2006) Minimally Invasive Approaches to Localized Prostate Carcinoma. Hematology/Oncology Clinics of North America 20:4, 879-895
CrossRef471
Gerald Andriole, Bob Djavan, Neil Fleshner, Fritz Schröder. (2006) The Case for Prostate Cancer Screening with Prostate-Specific Antigen. European Urology Supplements 5:12, 737-745
CrossRef472
André N. Vis, Fritz H. Schröder, Theodorus H. van der Kwast. (2006) The Actual Value of the Surgical Margin Status as a Predictor of Disease Progression in Men with Early Prostate Cancer. European Urology 50:2, 258-265
CrossRef473
Thomas D. Denberg, Trisha V. Melhado, John F. Steiner. (2006) Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote. Cancer 107:3, 620-630
CrossRef474
Gerald Andriole. (2006) 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond. European Urology Supplements 5:12, 746-751
CrossRef475
Patrick C. Walsh. (2006) Urological oncology: Prostate cancer. The Journal of Urology 176:2, 581-583
CrossRef476
Torvald Granfors, Hans Modig, Jan-Erik Damber, Radisa Tomic. (2006) Long-Term Followup of a Randomized Study of Locally Advanced Prostate Cancer Treated With Combined Orchiectomy and External Radiotherapy Versus Radiotherapy Alone. The Journal of Urology 176:2, 544-547
CrossRef477
Peter T Scardino. (2006) Surgery in elderly cancer patients. Nature Clinical Practice Urology 3:8, 397-397
CrossRef478
David Gillatt. (2006) Antiandrogen treatments in locally advanced prostate cancer: are they all the same?. Journal of Cancer Research and Clinical Oncology 132:S1, 17-26
CrossRef479
Sameer A. Siddiqui, Brant A. Inman, Shomik Sengupta, Jeffrey M. Slezak, Eric J. Bergstralh, Bradley C. Leibovich, Horst Zincke, Michael L. Blute. (2006) Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 107:3, 521-529
CrossRef480
Peter Albertsen. (2006) Against the motion. European Urology 50:2, 379-380
CrossRef481
John L Gore, David F Penson, Mark S Litwin. (2006) Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. Nature Clinical Practice Urology 3:8, 449-452
CrossRef482
Dragan Ilic, Denise O'Connor, Sally Green, Timothy J Wilt, Dragan Ilic. 2006. Screening for prostate cancer. .
CrossRef483
Renske Postma, Arno G.J.L.H. van Leenders, Monique J. Roobol, Fritz H. Schröder, Theodorus H. van der Kwast. (2006) Tumour Features in the Control and Screening Arm of A Randomized Trial of Prostate Cancer. European Urology 50:1, 70-75
CrossRef484
Michael P. Porter, Janet L. Stanford, Paul H. Lange. (2006) The Distribution of Serum Prostate-Specific Antigen Levels Among American Men: Implications for Prostate Cancer Prevalence and Screening. The Prostate 66:10, 1044-1051
CrossRef485
Richard E. Peschel, Anwar Khan, John Colberg, Lynn D. Wilson. (2006) The Effect of Age on Prostate Implantation Results. The Cancer Journal 12:4, 305-308
CrossRef486
PETER G. HAMMERER, MICHAEL W. KATTAN, NICOLAS MOTTET, TOMMASO PRAYER-GALETTI. (2006) Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU International 98:1, 11-19
CrossRef487
Richard Clements. (2006) Contemporary issues in the diagnosis of prostate cancer for the radiologist. European Radiology 16:7, 1580-1590
CrossRef488
P. Paula Hruska, Joel Picus. (2006) The role of primary chemotherapy for prostate cancer: Has the time come?. Current Urology Reports 7:3, 233-238
CrossRef489
V Bhatnagar, S T Stewart, V Huynh, G Jorgensen, R M Kaplan. (2006) Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer and Prostatic Diseases 9:2, 136-146
CrossRef490
C Parker, D Muston, J Melia, S Moss, D Dearnaley. (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. British Journal of Cancer 94:10, 1361-1368
CrossRef491
Anthony F. Shields. (2006) Positron Emission Tomography Measurement of Tumor Metabolism and Growth: Its Expanding Role in Oncology. Molecular Imaging and Biology 8:3, 141-150
CrossRef492
RAVISHANKAR JAYADEVAPPA, SUMEDHA CHHATRE, RICHARD WHITTINGTON, BERNARD S. BLOOM, ALAN J. WEIN, S. BRUCE MALKOWICZ. (2006) Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. BJU International 97:5, 955-962
CrossRef493
Philipp Dahm. (2006) Evidence-based medicine in prostate cancer: where do we stand in 2006?. Current Opinion in Urology 16:3, 162-167
CrossRef494
Chi-Wai Man. (2006) Editorial note. Don't procrastinate. Surgical Practice 10:2, 62-62
CrossRef495
Morgan Rouprêt, Gaëlle Fromont, Marc-Olivier Bitker, Bernard Gattegno, Guy Vallancien, Olivier Cussenot. (2006) Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 67:5, 1028-1032
CrossRef496
Bertrand Tombal. (2006) Over- and Underdiagnosis of Prostate Cancer: The Dangers. European Urology Supplements 5:6, 511-513
CrossRef497
Laurence Klotz, Robert Nam. (2006) Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: Clinical Experience and a “Number Needed to Treat” Analysis. European Urology Supplements 5:6, 479-486
CrossRef498
Ove Andrén, Katja Fall, Lennart Franzén, Swen-Olof Andersson, Jan-Erik Johansson, Mark A. Rubin. (2006) How Well Does the Gleason Score Predict Prostate Cancer Death? A 20-Year Followup of a Population Based Cohort in Sweden. The Journal of Urology 175:4, 1337-1340
CrossRef499
Prasanna Sooriakumaran, Sara Jane Khaksar, Jyoti Shah. (2006) Management of prostate cancer. Part 2: localized and locally advanced disease. Expert Review of Anticancer Therapy 6:4, 595-603
CrossRef500
Shira L. Galper, Ming-Hui Chen, William J. Catalona, Kimberly A. Roehl, Jerome P. Richie, Anthony V. D’Amico. (2006) Evidence to Support a Continued Stage Migration and Decrease in Prostate Cancer Specific Mortality. The Journal of Urology 175:3, 907-912
CrossRef501
C. Warlick, B. J. Trock, P. Landis, J. I. Epstein, H. B. Carter. (2006) Delayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome. JNCI Journal of the National Cancer Institute 98:5, 355-357
CrossRef502
G W Chodak, K S Warren. (2006) Watchful waiting for prostate cancer: a review article. Prostate Cancer and Prostatic Diseases 9:1, 25-29
CrossRef503
Peter S. Nelson, Bruce Montgomery. (2006) Cell type-specific analyses for identifying prostate cancer biomarkers. Current Urology Reports 7:1, 57-63
CrossRef504
Howard M Sandler. (2006) Adjuvant postoperative radiotherapy following radical prostatectomy: is now the time?. Nature Clinical Practice Oncology 3:2, 84-85
CrossRef505
Mirja Ruutu, Antti Rannikko. (2006) Incidence and Follow-Up of Patients with Focal Prostate Carcinoma in 2 Screening Rounds After an Interval of 4 Years. European Urology 49:2, 411
CrossRef506
PETER WHELAN. (2006) Radical prostatectomy versus watchful waiting. BJU International 97:2, 415-415
CrossRef507
Stacy Loeb, Kimberly A. Roehl, Jo Ann V. Antenor, William J. Catalona, Brian K. Suarez, Robert B. Nadler. (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67:2, 316-320
CrossRef508
Hiroyoshi Suzuki, Akira Komiya, Naoto Kamiya, Takashi Imamoto, Koji Kawamura, Junichiro Miura, Noriyuki Suzuki, Hiroomi Nakatsu, Akira Hata, Tomohiko Ichikawa. (2006) Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 67:1, 131-136
CrossRef509
Christopher A. Warlick, Mohamad E. Allaf, H. Ballentine Carter. (2006) Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy. Urologic Oncology: Seminars and Original Investigations 24:1, 51-57
CrossRef510
Laurence Klotz. (2006) Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urologic Oncology: Seminars and Original Investigations 24:1, 46-50
CrossRef511
M A Khan, A W Partin. (2005) Expectant management: an option for localized prostate cancer. Prostate Cancer and Prostatic Diseases 8:4, 311-315
CrossRef512
Arnauld Villers. (2005) What are the survival outcomes for prostate cancer in a population-based cohort of unscreened men?. Nature Clinical Practice Urology 2:12, 592-593
CrossRef513
Shomik Sengupta, Horst Zincke. (2005) Is radical prostatectomy of benefit in men with localized prostate cancer?. Nature Clinical Practice Oncology 2:12, 608-609
CrossRef514
Shabbir M.H. Alibhai, Sven Gogov. (2005) Radical prostatectomy for early prostate cancer improves long term survival. Cancer Treatment Reviews 31:8, 640-643
CrossRef515
MICHAEL MULLERAD, HEDVIG HRICAK, KENTARO KUROIWA, DARKO PUCAR, HUI-NI CHEN, MICHAEL W. KATTAN, PETER T. SCARDINO. (2005) COMPARISON OF ENDORECTAL MAGNETIC RESONANCE IMAGING, GUIDED PROSTATE BIOPSY AND DIGITAL RECTAL EXAMINATION IN THE PREOPERATIVE ANATOMICAL LOCALIZATION OF PROSTATE CANCER. The Journal of Urology 174:6, 2158-2163
CrossRef516
W Scott Webster, Bradley C Leibovich. (2005) Exisulind in the treatment of prostate cancer. Expert Review of Anticancer Therapy 5:6, 957-962
CrossRef517
Hatzimouratidis Konstantinos. (2005) Prostate Cancer in the Elderly. International Urology and Nephrology 37:4, 797-806
CrossRef518
Roger S. Kirby, John M. Fitzpatrick. (2005) Radical prostatectomy vs watchful waiting. BJU International 96:7, 953-954
CrossRef519
Jerome P. Richie. (2005) Radical prostatectomy vs watchful waiting in early prostate cancer. BJU International 96:7, 951-952
CrossRef520
Peter C Albertsen. (2005) What is the value of screening for prostate cancer in the US?. Nature Clinical Practice Oncology 2:11, 536-537
CrossRef521
James W Denham, Allison Steigler, David S Lamb, David Joseph, Hedy Mameghan, Sandra Turner, John Matthews, Ian Franklin, Chris Atkinson, John North, Michael Poulsen, David Christie, Nigel A Spry, Keen-Hun Tai, Chris Wynne, Gillian Duchesne, Olga Kovacev, Catherine D'Este. (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. The Lancet Oncology 6:11, 841-850
CrossRef522
Michael J. Barry. (2005) Revisiting my personal decision about prostate-specific antigen testing in 2005. BJU International 96:7, 954-956
CrossRef523
Roger S. Kirby, Michael Kirby. (2005) The urologist as an advocate of men’s health: 10 suggested steps toward helping patients achieve better overall health. Urology 66:5, 52-56
CrossRef524
Richard M Martin, George Davey Smith, Jenny Donovan. (2005) Does current evidence justify prostate cancer screening in Europe?. Nature Clinical Practice Oncology 2:11, 538-539
CrossRef525
Loren K. Mell, Arno J. Mundt. (2005) Radiation Therapy in the Elderly. The Cancer Journal 11:6, 495-505
CrossRef526
Scott R Gerst, Abdelkrim K Touijer, Bertrand Guillonneau, Hikmat Al-Ahmadie, Amir Mehdizade. (2005) The importance of MRI evaluation in the preoperative work-up of prostate cancer. Nature Clinical Practice Urology 2:11, 565-571
CrossRef527
Chris Parker. (2005) The Scandinavian prostate cancer group study: the case for conservative management. BJU International 96:7, 952-953
CrossRef528
S. M. H. Alibhai, M. Leach, G. Tomlinson, M. D. Krahn, N. Fleshner, E. Holowaty, G. Naglie. (2005) 30-Day Mortality and Major Complications after Radical Prostatectomy: Influence of Age and Comorbidity. JNCI Journal of the National Cancer Institute 97:20, 1525-1532
CrossRef529
William J. Catalona, Stacy Loeb. (2005) The PSA Era is not Over for Prostate Cancer. European Urology 48:4, 541-545
CrossRef530
Patrick C. Walsh. (2005) 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. The Journal of Urology 174:4, 1292-1293
CrossRef531
Eleanor Ray, Tim O'Brien. (2005) A survival benefit from radical prostatectomy for early prostate cancer. International Journal of Clinical Practice 59:10, 1122-1123
CrossRef532
(2005) Radical Prostatectomy versus Watchful Waiting. New England Journal of Medicine 353:12, 1298-1300
Full Text533
I. M. Thompson, E. Canby-Hagino, M. S. Lucia. (2005) Stage Migration and Grade Inflation in Prostate Cancer: Will Rogers Meets Garrison Keillor. JNCI Journal of the National Cancer Institute 97:17, 1236-1237
CrossRef534
Laurence Klotz. (2005) Can clinically localized prostate cancer be managed conservatively?. Nature Clinical Practice Urology 2:9, 416-417
CrossRef535
Andrew Vickers. (2005) Interpreting data from randomized trials: the Scandinavian prostatectomy study illustrates two common errors. Nature Clinical Practice Urology 2:9, 404-405
CrossRef536
Eric A Klein. (2005) Radical prostatectomy versus watchful waiting for early prostate cancer: finally, an answer. Nature Clinical Practice Urology 2:9, 412-413
CrossRef537
Stefan Höcht, Wolfgang Hinkelbein. (2005) Postoperative radiotherapy for prostate cancer. The Lancet 366:9485, 524-525
CrossRef538
William Dale, Pinar Bilir, Misop Han, David Meltzer. (2005) The role of anxiety in prostate carcinoma. Cancer 104:3, 467-478
CrossRef539
P. Albers. (2005) Studiensituation Uroonkologie. Der Urologe 44:8, 921-923
CrossRef540
J. A. Talcott. (2005) Employment After Therapy for Localized Prostate Cancer: Widening the Perspective. JNCI Journal of the National Cancer Institute 97:13, 948-949
CrossRef541
(2005) The treatment of early prostate cancer: 10-year follow-up. Nature Clinical Practice Urology 2:7, 312-312
CrossRef542
Roger Kirby. (2005) Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. Nature Clinical Practice Urology 2:6, 298-303
CrossRef543
Seymour Levitt. (2005) Second Acta Oncologia Symposium on Prostate Cancer Controversies. Acta Oncologica 44:6, 526-528
CrossRef
- Letters
